ATE92959T1 - Herstellung von chimaeren antikoerpern. - Google Patents

Herstellung von chimaeren antikoerpern.

Info

Publication number
ATE92959T1
ATE92959T1 AT85904274T AT85904274T ATE92959T1 AT E92959 T1 ATE92959 T1 AT E92959T1 AT 85904274 T AT85904274 T AT 85904274T AT 85904274 T AT85904274 T AT 85904274T AT E92959 T1 ATE92959 T1 AT E92959T1
Authority
AT
Austria
Prior art keywords
encodes
production
molecule
preparing
variable region
Prior art date
Application number
AT85904274T
Other languages
English (en)
Inventor
Michael Samuel Neuberger
Terence Howard Rabbitts
Original Assignee
Celltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10566192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE92959(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltech Ltd filed Critical Celltech Ltd
Application granted granted Critical
Publication of ATE92959T1 publication Critical patent/ATE92959T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT85904274T 1984-09-03 1985-09-03 Herstellung von chimaeren antikoerpern. ATE92959T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB848422238A GB8422238D0 (en) 1984-09-03 1984-09-03 Chimeric proteins
PCT/GB1985/000392 WO1986001533A1 (en) 1984-09-03 1985-09-03 Production of chimeric antibodies
EP85904274A EP0194276B2 (de) 1984-09-03 1985-09-03 Herstellung von chimären antikörpern

Publications (1)

Publication Number Publication Date
ATE92959T1 true ATE92959T1 (de) 1993-08-15

Family

ID=10566192

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85904274T ATE92959T1 (de) 1984-09-03 1985-09-03 Herstellung von chimaeren antikoerpern.

Country Status (6)

Country Link
EP (1) EP0194276B2 (de)
JP (2) JP2714786B2 (de)
AT (1) ATE92959T1 (de)
DE (1) DE3587524T3 (de)
GB (2) GB8422238D0 (de)
WO (1) WO1986001533A1 (de)

Families Citing this family (1125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1986005513A1 (en) * 1985-03-18 1986-09-25 Gene Labs, Inc. Hybrid-gene cassette vector
US5169939A (en) * 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
EP0536566A1 (de) * 1985-11-01 1993-04-14 Xoma Corporation Modulare Einheit von Antikörpergenen, daraus hergestellte Antikörper und Verwendung
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
EP0247091B1 (de) * 1985-11-01 1993-09-29 Xoma Corporation Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB2188941B (en) * 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
DE3751908T2 (de) * 1986-07-07 1997-02-06 Centocor Inc Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
CA1339445C (en) * 1986-11-12 1997-09-09 The General Hospital Corporation Recombinant hybrid immunoglobulin molecules and method of use
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ATE151638T1 (de) 1987-02-20 1997-05-15 Genentech Inc Verfahren und zubereitungen für die verwendung von hiv-env-polypeptiden und antikörpern
DE3800048A1 (de) * 1987-05-14 1988-11-24 Boehringer Mannheim Gmbh Verfahren zur bestimmung eines antikoerpers in menschlichen koerperfluessigkeiten
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
DE3853515T3 (de) * 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5981278A (en) * 1987-05-29 1999-11-09 Tanox, Inc. Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
US6657050B1 (en) 1987-05-29 2003-12-02 Tanox, Inc. Chimeric viral-neutralizing immunoglobulins
US5834599A (en) * 1987-05-29 1998-11-10 Tanox Biosystems, Inc. Immunoconjugates which neutralize HIV-1 infection
CA1341235C (en) * 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
JPS6439990A (en) * 1987-08-05 1989-02-10 Chisso Corp Fused gene by bonding aequorin gene to functional gene
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US4978745A (en) * 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US5428133A (en) * 1987-12-31 1995-06-27 Tanox Biosystems, Inc. Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5843708A (en) * 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
GB8800077D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
EP0325224B1 (de) * 1988-01-22 1996-07-31 ZymoGenetics, Inc. Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
AU3342689A (en) * 1988-03-24 1989-10-16 Igen Incorporated Luminescent chimeric proteins
USRE39760E1 (en) * 1988-03-31 2007-08-07 International Bio-Immune Systems Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5582862A (en) 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US4975369A (en) * 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
IL86278A (en) * 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
US5906936A (en) * 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US5770198A (en) * 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
WO1990006323A2 (en) * 1988-11-29 1990-06-14 Centocor, Inc. Chimeric proteins incorporating a metal binding protein
DE3900534A1 (de) * 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
US6309880B1 (en) * 1989-04-25 2001-10-30 Tanox, Inc. Antibodies specific for CD4-binding domain of HIV-1
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291160B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291161B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6680192B1 (en) 1989-05-16 2004-01-20 Scripps Research Institute Method for producing polymers having a preselected activity
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
IL94872A (en) * 1989-06-30 1995-03-30 Oncogen Monoclonal or chimeric antibodies that react with human carcinoma, recombinant proteins that contain their anti-binding site, pharmaceutical preparations and kits that contain the
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US5196320A (en) * 1989-09-20 1993-03-23 Abbott Biotech, Inc. Method of producing engineered binding proteins
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US7037496B2 (en) 1989-12-27 2006-05-02 Centocor, Inc. Chimeric immunoglobulin for CD4 receptors
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
GB9021671D0 (en) * 1990-10-05 1990-11-21 Unilever Plc Delivery of agents
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
EP0460607A3 (en) * 1990-06-05 1992-04-01 Bristol-Myers Squibb Company Novel monoclonal antibody to novel antigen associated with human tumors
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
US6399062B1 (en) * 1990-11-06 2002-06-04 The United States Of America As Represented By The Secretary Of The Navy Murine monoclonal antibody protective against Plasmodium vivax malaria
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
WO1992013069A1 (en) * 1991-01-21 1992-08-06 Imperial College Of Science, Technology & Medicine Test and model for alzheimer's disease
US5912170A (en) * 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US5843728A (en) * 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
CA2107553C (en) * 1991-04-05 2001-07-31 Nancy Lin Monoclonal antibodies to stem cell factor receptors
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
DE69230545T2 (de) * 1991-08-21 2000-07-06 Novartis Ag, Basel Antikörperderivate
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US6027725A (en) * 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
EP0571613B1 (de) * 1991-12-13 2003-09-17 Xoma Corporation Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5851787A (en) * 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5605811A (en) * 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
AU5670194A (en) * 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
DE69419721T2 (de) 1993-01-12 2000-04-27 Biogen, Inc. Rekombinante anti-vla4 antikörpermoleküle
WO1994028025A1 (en) 1993-05-28 1994-12-08 The Scripps Research Institute Methods and compositions for inhibiting cd14 mediated cell activation
US5674493A (en) * 1993-08-31 1997-10-07 Thomas Jefferson University Compositions and methods for targeting cells with A2R and A2R monoclonal antibodies
WO1995008336A1 (en) * 1993-09-22 1995-03-30 Nichols Institute Diagnostics Graves' ophthalmopathy associated antibodies, graves' ophthalmopathy orbital antigen, and methods of use thereof
DE69426571T2 (de) 1993-10-27 2001-08-09 Elan Pharm Inc TRANSGENE TIERE, DIE APP Allele mit der schwedischen Mutation beherbergen
CA2185162A1 (en) 1994-03-07 1995-09-14 Robert F. Halenback (Deceased) Compositions for the inhibition of tnf formation and uses thereof
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5614609A (en) * 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor
EP1985703A3 (de) 1994-11-02 2009-04-08 Allelix Neuroscience, Inc. Spezifische Peripherie-Nervensystem-Natriumkanäle, DNS-Kodierung dafür, Kristallisierung, Röntgenstrahldiffraktion, Computermolekülformung, rationales Drogendesign, Drogenscreening und Verfahren zur Herstellung und Verwendung davon
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
US6091001A (en) * 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) * 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6248555B1 (en) 1995-08-31 2001-06-19 The General Hospital Corporation Genetic alterations related to familial alzheimer's disease
JPH09124509A (ja) * 1995-10-27 1997-05-13 Sumitomo Electric Ind Ltd 肝炎治療剤
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6015662A (en) * 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US5714352A (en) * 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
AU720890B2 (en) 1996-05-31 2000-06-15 National American Red Cross, The Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
US6716974B1 (en) 1996-05-31 2004-04-06 Maine Medical Center Research Institute Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
CA2257357C (en) 1996-06-07 2010-04-13 Neorx Corporation Humanized antibodies with modified glycosylation
EP0939810B1 (de) 1996-07-12 2007-02-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Transkriptions zwischen faktor-2 tif2
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
ATE412740T1 (de) 1996-08-16 2008-11-15 Human Genome Sciences Inc Menschliches alpha-endokin
JP2001502895A (ja) * 1996-09-20 2001-03-06 ザ・ジェネラル・ホスピタル・コーポレイション アルファ―２―抗プラスミンに対するキメラ、ヒト化および一本鎖抗体
US7883872B2 (en) 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
CA2665133A1 (en) 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine .alpha.
EP1780277A1 (de) 1997-01-15 2007-05-02 Yeda Research And Development Company, Ltd. IFN Rezeptor 1 bindende Proteine, dafür kodierende DNA und Verfahren zur Regulierung der zellulären Antwort auf Interferone
ATE426018T1 (de) 1997-04-10 2009-04-15 Stichting Katholieke Univ Pca3, pca3-gene und verfahren zu ihrer verwendung
US6054567A (en) 1997-04-11 2000-04-25 The United States Of America As Represented By The Department Of Health And Human Services Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
CA2288430C (en) 1997-04-16 2013-04-09 Millennium Biotherapeutics, Inc. Crsp protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor
US6204252B1 (en) 1997-04-25 2001-03-20 Aquila Biopharmaceuticals, Inc. Characterization of granulocytic ehrlichia and methods of use
AU7023798A (en) 1997-04-30 1998-11-24 De Novo Enzyme Corporation Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
ATE487737T1 (de) 1997-05-30 2010-11-15 Human Genome Sciences Inc 32 humane sekretierte proteine
CA2206774A1 (en) 1997-06-16 1998-12-16 Rick E. Preddie "prionins", highly specific markers for noninvasive presymptomatic defection of tse diseases, and targets for therapeutic reagents to prevent and control tse diseases in animals and humans
EP2045322B1 (de) 1997-07-14 2015-07-01 Université de Liège Doppelmuskelbildung bei Säugetieren
US6103466A (en) * 1997-07-14 2000-08-15 University Of Liege Double-muscling in mammals
EP1015488B1 (de) 1997-09-17 2009-09-09 Human Genome Sciences, Inc. Interleukin-17 rezeptor-ähnliches protein
KR20010031713A (ko) 1997-11-03 2001-04-16 벤슨 로버트 에이치. 맥관형성 및 종양 성장 억제제인 맥관 내피 세포 성장억제제
CA2310892A1 (en) 1997-11-21 1999-06-03 Human Genome Sciences, Inc. Chemokine alpha-5
WO1999047538A1 (en) 1998-03-19 1999-09-23 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
JP2000000097A (ja) 1998-06-15 2000-01-07 Nippon Zoki Pharmaceut Co Ltd Ｎｅｆ結合蛋白質、該蛋白質をコードするＤＮＡ並びに該蛋白質に対するモノクローナル抗体
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
EA005682B1 (ru) 1998-10-06 2005-04-28 Марк Аарон Эмалфарб Трансформированные грибы, в частности рода chrysosporium, способные к синтезу гетерологичных полипептидов
DE69839740D1 (de) 1998-10-22 2008-08-28 Univ Montana Vakzine enthaltend Omp85 Proteine von Neisseria gonorrhoeae und Neisseria meningitidis
PL350909A1 (en) 1999-02-12 2003-02-10 Genetics Inst Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
JP2002537769A (ja) 1999-02-26 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトエンドカインαおよび使用方法
EP1179000A4 (de) 1999-02-26 2005-10-12 Millennium Pharm Inc Ausscheidungsproteine und ihre verwendung
DE19915057A1 (de) 1999-04-01 2000-10-19 Forschungszentrum Borstel Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
IL130225A0 (en) 1999-05-31 2000-06-01 Yissum Res Dev Co Novel uses of antibodies against ache and peptides thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
CA2379214A1 (en) 1999-07-27 2001-02-01 Unilever Plc Bleaching detergent compositions
CA2380331C (en) 1999-08-09 2012-11-20 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
CA2381770C (en) 1999-08-24 2007-08-07 Medarex, Inc. Human ctla-4 antibodies and their uses
US7368545B1 (en) 1999-09-29 2008-05-06 Diagnocure Inc. PCA3 messenger RNA species in benign and malignant prostate tissues
US7892541B1 (en) 1999-09-30 2011-02-22 Tumor Biology Investment Group, Inc. Soluble epidermal growth factor receptor isoforms
DK1234031T3 (en) 1999-11-30 2017-07-03 Mayo Foundation B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
CA2897626C (en) 2000-02-11 2020-03-24 Biogen Idec Ma Inc. Heterologous polypeptide of the tnf family
EP1276756A4 (de) 2000-04-12 2004-06-09 Human Genome Sciences Inc Albumin fusionsproteine
CA2399940A1 (en) 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
US7632929B2 (en) 2000-04-20 2009-12-15 The Board Of Trustees Of The University Of Arkansas Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
EP1714661A3 (de) 2000-05-19 2012-03-14 The Center for Blood Research, INC. Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
AU2001275378A1 (en) 2000-06-08 2001-12-17 The Center For Blood Research, Inc. Methods and compositions for inhibiting immunoglobulin-mediated reperfusion inj ury
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US6803211B2 (en) 2000-08-25 2004-10-12 Pfizer Inc. Methods and compositions for diagnosing and treating disorders involving angiogenesis
EP1349946B1 (de) 2000-08-25 2011-01-26 BASF Plant Science GmbH Polynukleotide, die für prenylproteasen aus pflanzen kodieren
JP5113314B2 (ja) 2000-09-01 2013-01-09 ザ センター フォー ブラッド リサーチ インク 所望のコンホメーションで安定させた改変ポリペプチド及び該ポリペプチドの作製方法
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
EP1421174B1 (de) 2000-10-18 2009-12-23 The Brigham And Women's Hospital, Inc. E-selectin/l-selectin-liganden-polypeptide hämatopoetischer zellen und verfahren zu deren verwendung
US7858559B2 (en) 2000-11-17 2010-12-28 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
BR0115715A (pt) 2000-11-28 2004-02-03 Wyeth Corp Análise de expressão de ácidos nucleìcos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
HUP0303905A3 (en) 2000-11-28 2005-11-28 Wyeth Corp Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2002046475A2 (en) 2000-12-08 2002-06-13 Curagen Corporation Method of detecting and treating tuberous sclerosis complex associated disorders
AU2002235761A1 (en) 2000-12-19 2002-07-01 Unilever Plc Stabilization of antibodies or fragments thereof
US7445802B2 (en) 2000-12-26 2008-11-04 Yeda Research And Development Co. Ltd Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
US20020132274A1 (en) 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
WO2002068673A2 (en) 2001-02-23 2002-09-06 Dana-Farber Cancer Institute, Inc. Hin-1, a tumor suppressor gene
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
WO2002079499A1 (en) 2001-04-02 2002-10-10 Wyeth Pd-1, a receptor for b7-4, and uses therefor
US7384775B2 (en) 2001-04-16 2008-06-10 Wyeth Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7744882B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 methods of detection and antibodies
US7745398B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 and treatment of cancer
JP4619651B2 (ja) 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
DE60233509D1 (de) 2001-06-20 2009-10-08 Fibron Ltd Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP3187592B1 (de) 2001-09-20 2018-12-12 Immunex Corporation Auswahl von heteromeren polypeptide exprimierenden zellen
CA2460916A1 (en) 2001-10-04 2003-04-10 Laura Carter Methods and compositions for modulating interleukin-21 receptor activity
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DE10151511A1 (de) 2001-10-18 2003-05-08 Basf Lynx Bioscience Ag ee3-Proteinfamilie und zugrundeliegende DNA-Sequenzen
EP1944043A1 (de) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Nukleinsäure- und Aminosäuresequenzen von Affen-Adenoviren, hergeleitete Vektoren und Verwendungsverfahren.
CA2468733C (en) 2001-11-30 2013-06-11 Biogen Idec Ma Inc. Antibodies against monocyte chemotactic proteins
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
WO2003049673A2 (en) 2001-12-05 2003-06-19 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
ES2337989T3 (es) 2001-12-18 2010-05-03 Endocube Sas Nuevas proteinas asociadas a la muerte de la familia thap y rutas par4 relacionadas implicadas en el control de la apoptosis.
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
EP1463807A4 (de) 2001-12-19 2006-04-12 Bristol Myers Squibb Co Formiatdehydrogenase aus pichia pastoris und verwendungen dafür
JP2005526233A (ja) 2001-12-31 2005-09-02 ダナ−ファーバー　キャンサー　インスティテュート，インコーポレイテッド 乳房上皮細胞によるソライアシン発現を用いた方法
EP2292247A3 (de) 2002-03-05 2011-10-05 Ramot at Tel Aviv University Ltd. Immunisierende zusammensetzung und verfahren zur auslösung einer immunantwort gegen die beta-secretase-cleavage-stelle von amyloid-vorläuferprotein
GB0207533D0 (en) 2002-04-02 2002-05-08 Oxford Glycosciences Uk Ltd Protein
JP2005535572A (ja) 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
JP2006511194A (ja) 2002-05-02 2006-04-06 デイビッド ラブジョイ テネウリンｃ末端関連ペプチド（ｔｃａｐ）並びにこれらに関連する方法および使用
WO2003097798A2 (en) 2002-05-14 2003-11-27 Martek Biosciences Corporation Carotene synthase gene and uses therefor
AU2003240790A1 (en) 2002-05-28 2003-12-12 Pharmacia Corporation Antibody peg positional isomers, compositions comprising same, and use thereof
JP4643255B2 (ja) 2002-06-10 2011-03-02 バクシネックス インコーポレーティッド 乳癌および膀胱癌において差次的に発現される遺伝子ならびにコードされるポリペプチド
WO2003106656A2 (en) 2002-06-17 2003-12-24 Thrasos, Inc. Single domain tdf-related compounds and analogs thereof
US7250551B2 (en) 2002-07-24 2007-07-31 President And Fellows Of Harvard College Transgenic mice expressing inducible human p25
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
EP2181595A1 (de) 2002-08-16 2010-05-05 Yeda Research And Development Company Ltd. Tumorassoziiertes Antigen, Peptide davon, und deren Verwendung als Antitumorimpfstoffe
EP2311978A1 (de) 2002-08-20 2011-04-20 Millennium Pharmaceuticals, Inc. Zusammensetzungen, Kits und Verfahren zur Identifizierung, Beurteilung, Vorbeugung und Therapie von Gebärmutterhalskrebs
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7563771B2 (en) 2002-11-13 2009-07-21 Uab Research Foundation Synthetic single domain polypeptides mimicking apolipoprotein E
EP2112229A3 (de) 2002-11-25 2009-12-02 Sequenom, Inc. Verfahren zum Identifizieren des Brustkrebsrisikos und zugehörige Behandlungen
EP1581629B1 (de) 2002-12-06 2015-04-01 Millennium Pharmaceuticals, Inc. Verfahren zur identifizierung,beurteilung und behandlung von patienten mit einer proteasomen inhibitions therapie
PT2311848E (pt) 2002-12-23 2013-10-03 Vical Inc Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano
US8557957B2 (en) 2003-01-03 2013-10-15 Elizabeth Kornecki Methods of treating disorders by administration of F11 receptor antagonists
US20050265992A1 (en) 2003-01-03 2005-12-01 The Research Foundation Of State University Of New York F11 receptor (F11R) antagonists as therapeutic agents
US8206931B2 (en) 2003-01-17 2012-06-26 The Johns Hopkins University Methods of identifying modulators of cellular glycosylation using GTRAP3-18
ATE552860T1 (de) 2003-01-31 2012-04-15 Celldex Res Corp Antikörper-vakzine-konjugate und ihre verwendungen
US9259459B2 (en) 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
ES2427853T3 (es) 2003-02-07 2013-11-04 Diagnocure Inc. Procedimiento para detectar cáncer de próstata en una muestra
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
US20040180387A1 (en) 2003-03-13 2004-09-16 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
SE0301087D0 (sv) 2003-04-14 2003-04-14 Cartela Ab New monoclonal antibody
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
EP2829283B1 (de) 2003-04-30 2017-06-07 Universität Zürich Verfahren zur Behandlung von Krebs unter Verwendung eines Immuntoxins
PT2374819T (pt) 2003-05-12 2017-07-04 Helion Biotech Aps Anticorpos para masp-2
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US8080642B2 (en) 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
EP1635763B1 (de) 2003-06-09 2012-08-08 Alnylam Pharmaceuticals Inc. Verfahren zur behandlung von neurodegenerativen erkrankungen
US7871768B2 (en) 2003-08-04 2011-01-18 The Hospital For Sick Children Lafora's disease gene
IL158287A0 (en) 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
MXPA06003402A (es) 2003-10-07 2006-06-27 Millennium Pharm Inc Moleculas de acidos nucleicos y proteinas para la identificacion, evaluacion, prevencion y tratamiento de cancer de ovario.
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
WO2005047475A2 (en) 2003-11-11 2005-05-26 Regents Of The University Of Minnesota Regulation of cell membrane-mediated effects
JP4833850B2 (ja) 2003-11-21 2011-12-07 ユセベ ファルマ ソシエテ アノニム Ｉｌ−１７活性阻害による多発性硬化症を治療するための方法
EP1631311A4 (de) 2003-12-10 2007-04-11 Millennium Pharm Inc Humanisierte anti-ccr2-antikörper und anwendungsverfahren
CA2494572A1 (en) 2003-12-19 2005-06-19 Cytochroma Inc. Cytochrome p450 24 (cyp24) monoclonal antibody and methods and uses thereof
WO2005063992A1 (ja) 2003-12-30 2005-07-14 Suntory Limited 新規血清型のストレプトコッカス ミュータンスおよびその利用
TR201815885T4 (tr) 2004-01-07 2018-11-21 Novartis Vaccines & Diagnostics Inc M-csf spesifik monoklonal antikorlar ve bunların kullanımı.
EP2444805A3 (de) 2004-01-21 2012-06-20 Fujirebio America, Inc. Erkennung von Mesothelin-/Megakaryozyten zur Potenzierung von faktorbezogenen Peptiden in peritonealer Flüssigkeit zur Bewertung des Peritoneum und Peritonealhöhle
AU2005206277B2 (en) 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
KR20120083534A (ko) 2004-02-06 2012-07-25 메다렉스, 인코포레이티드 클로스트리듐 디피실리 독소에 대한 항체 및 이의 용도
PL1713503T3 (pl) 2004-02-10 2014-02-28 Univ Colorado Regents Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby
EP2290077B1 (de) 2004-03-01 2016-01-27 Immune Disease Institute, Inc. Natürliche IgM-Antikörper und Inhibitoren
AU2005224081B2 (en) 2004-03-12 2011-06-30 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
CA2560742A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
ES2442386T3 (es) 2004-04-23 2014-02-11 Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr Método para el tratamiento de condiciones mediadas por células T por la disminución de las células positivas de ICOS in vivo.
JP4836942B2 (ja) 2004-04-30 2011-12-14 コーセラ， インコーポレイテッド リラキシンの調節による胎仔の発育の制御のための方法および組成物
EP1598428A1 (de) 2004-05-18 2005-11-23 Georg Dewald Verfahren und Kits zum Nachweis von erblichen angioedema typ III
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
WO2005115992A1 (en) 2004-05-23 2005-12-08 Housey Pharmaceuticals, Inc. Theramutein modulators
KR100620554B1 (ko) 2004-06-05 2006-09-06 한국생명공학연구원 Ｔａｇ-72에 대한 인간화 항체
EP2319526A1 (de) 2004-06-17 2011-05-11 Thrasos Therapeutics, Inc. TDF-ähnliche Verbindungen und deren Analogal
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
US7973134B2 (en) 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
EP2287310B1 (de) 2004-07-22 2015-05-06 Five Prime Therapeutics, Inc. Zusammensetzungen und Verfahren zur Verwendung von MGD-CSF zur Krankheitsbehandlung
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US7935790B2 (en) 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
PL1810026T3 (pl) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego
NZ554520A (en) 2004-10-22 2010-03-26 Amgen Inc Methods for refolding of recombinant antibodies
AU2005332660A1 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
US7807789B2 (en) 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
JP2008532493A (ja) 2005-02-14 2008-08-21 ワイス Ｉｌ−１７ｆとｉｌ−１７ｒとの間の相互作用の特性解析
EP1695981A1 (de) 2005-02-25 2006-08-30 Forschungsverbund Berlin e.V. Verfahren zum Redox-Potential-abhängigen Nachweis von Targetmolekülen durch wechselwirkende Polypeptide
US7829673B2 (en) 2005-03-23 2010-11-09 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
AU2006236225C1 (en) 2005-04-19 2013-05-02 Seagen Inc. Humanized anti-CD70 binding agents and uses thereof
WO2006117782A2 (en) 2005-05-04 2006-11-09 Quark Pharmaceuticals, Inc. Recombinant antibodies against cd55 and cd59 and uses thereof
WO2006125076A2 (en) 2005-05-18 2006-11-23 Trinity Biosystems, Inc. Methods and compositions for immunizing against chlamydia infection
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
BRPI0618160A2 (pt) 2005-05-26 2011-08-16 Univ Colorado inibição da via alternativa complemento para tratamento de danos cerebrais traumáticos, danos na medula espinhal e condições relacionadas
CA2608504A1 (en) 2005-05-31 2006-12-07 Duska Scientific Co. Inhibition of neuronal damage
EP2364998A1 (de) 2005-06-16 2011-09-14 The Feinstein Institute for Medical Research Antikörper gegen HMGB1 und Fragmente davon
EP1896504B1 (de) 2005-06-17 2012-11-21 Wyeth LLC VERFAHREN ZUR REINIGUNG FC-REGIONSHALTIGER ANTIKöRPER
SI2314623T1 (sl) 2005-06-21 2012-11-30 Xoma Technology Ltd IL beta vezavna protitelesa in njihovi fragmenti
EP2722051B1 (de) 2005-07-07 2018-11-07 Seattle Genetics, Inc. Monomethylvalinverbindungen mit Phenylalaninseitenkettenmodifikationen am C-Terminus
CA2616005C (en) 2005-07-18 2015-09-22 Seattle Genetics, Inc. Beta-glucuronide-linker drug conjugates
SG164379A1 (en) 2005-07-21 2010-09-29 Genmab As Potency assays for antibody drug substance binding to an fc receptor
EP1913027B1 (de) 2005-07-28 2015-03-04 Novartis AG M-csf-spezifische monoklonale antikörper und anwendungen davon
EP1934867A2 (de) 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reagentien zum nachweis der proteinphosphorylierung in leukämie-signalwegen
WO2007035872A2 (en) 2005-09-20 2007-03-29 Thrasos Therapeutics, Inc. Tdf-related compounds and analogs thereof
DE602006021768D1 (de) 2005-09-28 2011-06-16 Dickinson & Co Nachweis von lysophosphatidylcholin für die prognose oder diagnose eines systemischen entzündungszustands
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
EP2860192B1 (de) 2005-10-12 2017-09-27 MorphoSys AG Gewinnung und Profilierung von vollständig humanen, von HuCAL GOLD-abgeleiteten therapeutischen Antikörpern für humanes CD38
US8597646B2 (en) 2005-10-25 2013-12-03 The Johns Hopkins University Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders
CA2626804A1 (en) 2005-11-01 2007-08-09 Abbott Biotechnology Ltd. Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
WO2007055916A2 (en) 2005-11-07 2007-05-18 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
EA014900B1 (ru) 2005-11-07 2011-02-28 Зе Скрипс Ресеч Инститьют Композиции и способы контроля специфичности передачи сигналов, опосредуемой тканевым фактором
JP5415767B2 (ja) 2005-11-10 2014-02-12 ボード オブ スーパーバイザーズ オブ ルイジアナ ステイト ユニバーシティー アンド アグリカルチュラル アンド メカニカル カレッジ 依存症及び他の精神神経疾患の治療のための組成物及び方法
EP1949109B1 (de) 2005-11-14 2012-02-29 MetaMol Theranostics, LLC Tumorinvasionsfördernde peptidsequenz
EP2336181A1 (de) 2005-12-09 2011-06-22 UCB Pharma, S.A. Antikörpermoleküle mit menschlicher IL-6-Spezifizität
EP3366702B1 (de) 2005-12-13 2023-08-09 Eli Lilly And Company Anti-il-17-antikörper
US20070264687A1 (en) 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
DK1991273T4 (da) 2006-02-10 2022-02-07 Life Technologies Corp Mærkning og påvisning af post-translationelt modificerede proteiner
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
AU2007225044C1 (en) 2006-03-15 2018-03-29 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
EP1854477B9 (de) 2006-03-16 2018-03-14 Dyax Corp. Peptid-Inhibitoren von Plasma Kallikrein zur Verwendung in der Behandlung von Augenerkrankungen
JP2009532358A (ja) 2006-03-31 2009-09-10 マサチューセッツ・インスティテュート・オブ・テクノロジー 突然変異型ｅｇｆ受容体を発現する腫瘍の治療
KR20140071452A (ko) 2006-04-05 2014-06-11 애브비 바이오테크놀로지 리미티드 항체 정제
EP2007426A4 (de) 2006-04-10 2010-06-16 Abbott Biotech Ltd Anwendungen und zusammensetzungen zur behandlung von psoriasis-arthritis
EP2666479A3 (de) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von juveniler rheumatoider Arthritis
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
WO2007124133A2 (en) 2006-04-20 2007-11-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated Methods and compositions based on shiga toxin type 1 protein
AU2007249698A1 (en) 2006-05-15 2007-11-22 University Of Kentucky Toll-like receptor (TLR) stimulation for ocular angiogenesis and macular degeneration
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US8796429B2 (en) 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US20080138334A1 (en) 2006-05-31 2008-06-12 Sabbadini Roger A Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same
EP2035439A4 (de) 2006-06-05 2010-01-13 Cancer Care Ontario Abschätzung des risikos von colorectalkrebs
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
ES2415655T3 (es) 2006-06-15 2013-07-26 The Board Of Trustees Of The University Of Arkansas Anticuerpos monoclonales que reconocen selectivamente Metanfetamina y compuestos similares a Metanfetamina
WO2007144893A2 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
AU2007264672B2 (en) 2006-06-28 2013-03-14 Hadasit Medical Research Services & Development Ltd Caspase-8 and inflammation, infection and wound healing
TWI527603B (zh) 2006-06-30 2016-04-01 艾伯維生物技術有限責任公司 自動注射裝置
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2008003319A1 (en) 2006-07-04 2008-01-10 Genmab A/S Cd20 binding molecules for the treatment of copd
WO2008003515A1 (en) 2006-07-07 2008-01-10 Intercell Ag Small streptococcus pyogenes antigens and their use
DK3255141T3 (da) 2006-07-13 2022-01-31 Wyeth Llc Fremstilling af antistoffer med forbedret glycosyleringsmønster
EP2420252A1 (de) 2006-08-04 2012-02-22 Novartis AG EPHB3-spezifischer Antikörper und Verwendungen davon
US7939636B2 (en) 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
CA2661023C (en) 2006-08-18 2017-08-15 Novartis Ag Prlr-specific antibody and uses thereof
US20090203602A1 (en) 2006-09-01 2009-08-13 Cohava Gelber Compositions and methods for diagnosis and treatment of type 2 diabetes
US7951776B2 (en) 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
EP2913342A1 (de) 2006-09-05 2015-09-02 Alexion Pharmaceuticals, Inc. Zusammensetzungen zur behandlung von antikörpervermittelten neuropathien
BRPI0716762A2 (pt) 2006-09-13 2013-09-24 Abbott Lab melhorias da cultura celular
EP2500416A1 (de) 2006-09-13 2012-09-19 Abbott Laboratories Verbesserungen an Zellkulturen
SI2081595T1 (sl) 2006-09-26 2019-10-30 Genmab As Anti-cd38 plus kortikosteroidi plus ne-kortikosteroidni kemoterapevtik za zdravljenje tumorjev
US20120282245A1 (en) 2006-10-03 2012-11-08 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
BRPI0719250A2 (pt) 2006-10-12 2015-06-16 Wyeth Corp Métodos e composições com opalescência reduzida.
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
RU2460541C2 (ru) 2006-10-27 2012-09-10 Лпат, Инк. Композиции и способы связывания сфингозин-1-фосфата
CA2667706A1 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
WO2008055260A2 (en) 2006-11-03 2008-05-08 Wyeth Glycolysis-inhibiting substances in cell culture
US20110294782A1 (en) 2006-11-10 2011-12-01 Massachusetts Institute Of Technology Small molecule pak inhibitors
JP2010510235A (ja) 2006-11-15 2010-04-02 ファンクショナル・ジェネティクス・インコーポレーテッド 抗ｔｓｇ１０１抗体およびウイルス感染の処置のためのその使用
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
EA200900767A1 (ru) 2006-12-07 2009-12-30 Новартис Аг Антагонистические антитела против ephb3
JP2010512324A (ja) 2006-12-08 2010-04-22 アッテヌオン エル エル シー ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法
EP2505651A3 (de) 2006-12-10 2013-01-09 Dyadic International, Inc. Pilzisolate mit reduzierter Proteaseaktivität
US7695718B2 (en) 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
JP5694668B2 (ja) 2006-12-29 2015-04-01 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 自己免疫疾患の診断上および治療上の標的ならびにその用途
EP2115173B1 (de) 2007-01-08 2011-09-21 Government of the USA, as Represented by the Secretary, Department of Health and Human Services Slco1b3-genotyp
US8343510B2 (en) 2007-01-12 2013-01-01 Intercell Ag Protective proteins of S. agalactiae, combinations thereof and methods of using the same
ATE526017T1 (de) 2007-01-22 2011-10-15 Genentech Inc Abscheidung von polyelektrolyten und reinigung von antikörpern
WO2008098139A2 (en) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
JP5662684B2 (ja) 2007-02-16 2015-02-04 ジェンザイム コーポレーション 甲状腺障害リスクの同定方法
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EP3118221B1 (de) 2007-02-26 2019-08-21 Oxford BioTherapeutics Ltd Proteine
PT2115126E (pt) 2007-03-02 2015-08-24 Wyeth Llc Utilização de cobre e glutamato na cultura de células para a produção de polipeptídeos
WO2008106785A1 (en) 2007-03-05 2008-09-12 Cancer Care Ontario Assessment of risk for colorectal cancer
US20090081659A1 (en) 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1975184A3 (de) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Serin- oder Threonin-Phosphorylationsorte
EP1983003A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylationsstellen und spezifische Antikörper
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP1983002A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylations-Stellen und spezifische Antikörper
WO2008131216A1 (en) 2007-04-20 2008-10-30 The Board Of Trustees Of The University Of Arkansas Hapten compounds and compositions and uses thereof
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
AU2008248755A1 (en) 2007-05-02 2008-11-13 Intercell Ag Klebsiella antigens
WO2008143797A1 (en) 2007-05-11 2008-11-27 Genzyme Corporation Methods of producing a secreted protein
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
EP2164992B1 (de) 2007-05-30 2016-05-04 Lpath, Inc. Zusammensetzungen und verfahren zur bindung von lysophosphatidinsäure
CA2688275A1 (en) 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
US20080317768A1 (en) 2007-06-21 2008-12-25 Boeing Company Bioconjugated nanoparticles
WO2009020632A1 (en) 2007-08-06 2009-02-12 Burnham Institute For Medical Research Znf206: a novel regulator of embryonic stem cell self-renewal and pluripotency
JP5749009B2 (ja) 2007-08-13 2015-07-15 バスジーン セラピューティクス，インコーポレイテッドＶａｓｇｅｎｅｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ＥｐｈＢ４に結合するヒト化抗体を利用する癌治療剤
WO2009033071A2 (en) 2007-09-07 2009-03-12 Dyadic International, Inc. Novel fungal enzymes
EP2197911A2 (de) 2007-09-14 2010-06-23 Amgen Inc. Homogene antikörperpopulationen
EP2567969A1 (de) 2007-09-24 2013-03-13 Cornell University Immunogene Proteine aus der genombasierten äußeren Membran von Leptospira sowie darauf basierende Zusammensetzungen und Verfahren
WO2009041501A1 (ja) 2007-09-27 2009-04-02 Virus Ikagaku Kenkyusho Inc. ヘルペスウイルスの潜伏感染に関与する因子及びその利用
GB0719231D0 (en) 2007-10-03 2007-11-14 Oxford Genome Sciences Uk Ltd Protein
US8361465B2 (en) 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
NZ585556A (en) 2007-11-07 2012-07-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
US8415361B2 (en) 2007-11-09 2013-04-09 The Salk Institute For Biological Studies Use of TAM receptor inhibitors as antimicrobials
US20090203043A1 (en) 2007-11-21 2009-08-13 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
EP2808345A3 (de) 2007-12-05 2015-03-11 Massachusetts Institute of Technology Aglycosylierte Immunoglobulinmutanten
MX2010006823A (es) 2007-12-20 2010-09-30 Xoma Technology Ltd Metodos para el tratamiento de la gota.
AU2008345022B2 (en) 2007-12-28 2014-11-06 Prothena Biosciences Limited Treatment and prophylaxis of amyloidosis
SI2242769T1 (sl) 2008-01-11 2017-02-28 Adheron Therapeutics, Inc. Protitelesa anti-kadherin-11 EC domene za zdravljenje vnetnih obolenj sklepov
ES2796085T3 (es) 2008-01-15 2020-11-25 Univ Leland Stanford Junior Marcadores de células madre de leucemia mieloide aguda
WO2009092806A2 (en) 2008-01-25 2009-07-30 Aarhus Universitet Selective exosite inhibition of papp-a activity against igfbp-4
JP2011514167A (ja) 2008-03-17 2011-05-06 インターセル アーゲー 肺炎連鎖球菌（Ｓ．ｐｎｅｕｍｏｎｉａｅ）に対して保護的なペプチドならびにそれに関連する組成物、方法、および使用
WO2009117531A1 (en) 2008-03-18 2009-09-24 Seattle Genetics, Inc. Auristatin drug linker conjugates
WO2009126306A2 (en) 2008-04-10 2009-10-15 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
EP3062106B1 (de) 2008-04-16 2020-11-11 The Johns Hopkins University Verfahren zur bestimmung von varianten des andorgen rezeptors in prostatakrebs
WO2009129502A2 (en) 2008-04-18 2009-10-22 The General Hospital Corporation Immunotherapies employing self-assembling vaccines
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
AU2009242453B2 (en) 2008-05-02 2014-12-04 Seagen Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
EP2650014A2 (de) 2008-06-20 2013-10-16 Wyeth LLC Zusammensetzungen und Verfahren zur Verwendung von ORF1358 von Beta-hämolytischen Streptokokken-stämmen
EP2307042B1 (de) 2008-06-25 2014-03-26 H. Lundbeck A/S Modulierung des trpv : vps10p domänen-rezeptorsystems zur behandlung von schmerzen
JP6100463B2 (ja) 2008-06-25 2017-03-22 エスバテック − ア ノバルティス カンパニー エルエルシー ＴＮＦαを阻害する安定かつ可溶性の抗体
CN102164958A (zh) 2008-06-25 2011-08-24 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 使用通用抗体构架进行的兔抗体的人源化
EP2982695B1 (de) 2008-07-09 2019-04-03 Biogen MA Inc. Zusammensetzungen mit antikörpern gegen lingo oder fragmenten davon
US8148088B2 (en) 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
JP2012504939A (ja) 2008-09-23 2012-03-01 ワイス・エルエルシー 架橋結合タンパク質による活性化シグナルの産生を予測するための方法
CA2998281C (en) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Human anti-pd-1 antobodies and uses therefor
EP2346525A4 (de) 2008-10-02 2012-05-09 Celtaxsys Inc Verfahren zur modulation der negativen chemotaxis von immunzellen
SI3335728T1 (sl) 2008-10-10 2020-04-30 Children's Medical Center Corporation Biokemično stabilizirano HIV-1 ENV trimer cepivo
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
EP4104821A1 (de) 2008-10-29 2022-12-21 Ablynx N.V. Formulierungen von einzeldomänen-antigen-bindenden molekülen
EP2346904B1 (de) 2008-10-29 2017-04-12 China Synthetic Rubber Corporation Methoden und mittel zur diagnose und behandlung von hepatozellulärem karzinom
JP6113404B2 (ja) 2008-10-29 2017-04-12 アブリンクス エン．ヴェー． 単一ドメイン抗原結合分子の精製方法
DK2356135T3 (en) 2008-11-05 2017-12-04 Wyeth Llc IMMUNOGEN MULTICOMPONENT COMPOSITION FOR THE PREVENTION OF BETA-HAEMOLYTIC STRUCTURAL TOC (BHS) DISEASE
CN102292101A (zh) 2008-11-26 2011-12-21 五佳医疗股份有限公司 通过serpine2来调节胶原和平滑肌肌动蛋白表达的组合物和方法
AU2009323996A1 (en) 2008-12-03 2011-07-07 Institut Pasteur Use of phenol-soluble modulins for vaccine development
US8401799B2 (en) 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
EP3165537A1 (de) 2008-12-19 2017-05-10 H. Lundbeck A/S Modulation der vps-10-domänen-rezeptor-familie für die behandlung von psychischen und verhaltensstörungen
US20120003235A1 (en) 2008-12-31 2012-01-05 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
US9181315B2 (en) 2009-01-08 2015-11-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
WO2010084408A2 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
US8313915B2 (en) 2009-01-21 2012-11-20 Gundersen Lutheran Medical Foundation, Inc. Early detection of canine lyme disease by specific peptides and antibodies
US8530629B2 (en) 2009-01-30 2013-09-10 Ab Biosciences, Inc. Lowered affinity antibodies and uses therefor
CA2983133A1 (en) 2009-02-04 2010-08-12 Molecular Innovations Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
CN102741287B (zh) 2009-02-17 2015-02-18 Ucb制药公司 对人ox40具有特异性的抗体分子
US20110306069A1 (en) 2009-02-19 2011-12-15 Qingyu Wu Corin As A Marker For Heart Failure
ES2589769T3 (es) 2009-02-27 2016-11-16 Massachusetts Institute Of Technology Proteínas modificadas con alta afinidad por quelatos de DOTA
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
JP2010213694A (ja) 2009-03-12 2010-09-30 Wyeth Llc ＰＫＮ３／ＲｈｏＣ高分子複合体およびその使用方法
JP2012522749A (ja) 2009-04-01 2012-09-27 グラクソ グループ リミテッド 抗ｉｌ−２３免疫グロブリン
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
EP3061460A1 (de) 2009-04-10 2016-08-31 Tufts Medical Center, Inc. Par-1-aktivierung mittels metalloproteinase-1 (mmp-1)
US20120135005A1 (en) 2009-04-16 2012-05-31 Harding Fiona A ANTI-TNF-a ANTIBODIES AND THEIR USES
WO2010121093A2 (en) 2009-04-17 2010-10-21 Lpath, Inc. Humanized antibody compositions and methods for binding lysophosphatidic acid
EP3524275A1 (de) 2009-04-22 2019-08-14 Massachusetts Institute Of Technology Angeborene immununterdrückung ermöglicht die wiederholte verabreichung von langen rna-molekülen
JP5781501B2 (ja) 2009-04-22 2015-09-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 改変されたＦｃＲｎ結合部位を有する抗体融合タンパク質
ES2598006T3 (es) 2009-04-24 2017-01-24 Vanderbilt University Anticuerpos anti-TGF-beta para la inducción del crecimiento óseo
ES2725356T3 (es) 2009-04-29 2019-09-23 Henry M Jackson Found Advancement Military Medicine Inc Anticuerpos monoclonales de ERG2 y su uso terapéutico
CN102459628A (zh) 2009-05-13 2012-05-16 基酶有限公司 抗人cd52 免疫球蛋白
PE20120622A1 (es) 2009-06-17 2012-05-26 Abbott Biotherapeutics Corp Anticuerpos anti-vegf y sus usos
EP2445531A4 (de) 2009-06-24 2013-04-24 Lpath Inc Verfahren für erhöhte neuronale differenzierung mithilfe von antikörpern gegen lysophosphatidsäure
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
EP2272979A1 (de) 2009-06-30 2011-01-12 Centre National de la Recherche Scientifique (CNRS) Verfahren zum Testen einer Person, die eine Prädisposition für Krebs aufzuweisen scheint
US20120226119A1 (en) 2009-07-09 2012-09-06 Hoffmann-La Roche Inc. Vivo tumor vasculature imaging
EP2475682B1 (de) 2009-09-10 2018-01-31 UCB Biopharma SPRL Polyvalente antikörper
EP2477647B1 (de) 2009-09-14 2016-01-13 The Regents of the University of Colorado Modulation von immuntherapeutischen produkten auf hefebasis und reaktionen
EP2470564A1 (de) 2009-10-22 2012-07-04 Yeda Research and Development Co. Ltd. Zusammensetzungen und verfahren zur behandlung von aspergillose
EP2493929B1 (de) 2009-10-28 2017-08-16 AbbVie Biotherapeutics Inc. Anti-egfr-antikörper und deren verwendungen
US20120282177A1 (en) 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
WO2011054359A2 (en) 2009-11-06 2011-05-12 University Of Copenhagen Method for early detection of cancer
CA3061784C (en) 2009-11-13 2023-09-26 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
US9872905B2 (en) 2009-12-01 2018-01-23 President And Fellows Of Harvard College Modulation of NK cell antigen specific effector activity by modulation of CXCR6 (CD186)
WO2011071883A1 (en) 2009-12-07 2011-06-16 Decimmune Therapeutics, Inc. Anti-inflammatory antibodies and uses therefor
WO2011075578A1 (en) 2009-12-16 2011-06-23 Philip Bosch Methods of treating interstitial cystitis
ES2594893T3 (es) 2009-12-16 2016-12-23 Abbvie Biotherapeutics Inc. Anticuerpos anti HER2 y sus usos
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
JP2013520162A (ja) 2010-01-22 2013-06-06 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 代謝障害の同定、査定、予防および治療のための組成物、キットおよび方法
CN102971342B (zh) 2010-01-28 2016-08-03 Ab生物科学公司 亲和力降低的新抗体和制备所述抗体的方法
CA2789168A1 (en) 2010-02-02 2011-08-11 Abbott Biotechnology Ltd. Methods and compositions for predicting responsiveness to treatment with tnf-.alpha. inhibitor
TWI518325B (zh) 2010-02-04 2016-01-21 自治醫科大學 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
WO2011106885A1 (en) 2010-03-03 2011-09-09 The University Of British Columbia Oligomer-specific amyloid beta epitope and antibodies
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
US8993731B2 (en) 2010-03-11 2015-03-31 Ucb Biopharma Sprl PD-1 antibody
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
US10472426B2 (en) 2010-03-25 2019-11-12 Ucb Biopharma Sprl Disulfide stabilized DVD-Ig molecules
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
NZ602634A (en) 2010-03-26 2015-06-26 Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
EP2556374A1 (de) 2010-04-05 2013-02-13 Wyeth LLC Biomarker für p13k-ausgelösten krebs
SI3202789T1 (sl) 2010-04-16 2020-11-30 Biogen Ma Inc. Protitelesa anti-vla 4
CA2796186C (en) 2010-04-21 2019-04-09 Abbott Biotechnology Ltd. Wearable automatic injection device for controlled delivery of therapeutic agents
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
EP2380909A1 (de) 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. An Brustkrebs beteiligtes Protein PTK-7
US9146241B2 (en) 2011-11-23 2015-09-29 Board Of Regents, The University Of Texas System Proteomic identification of antibodies
WO2011146727A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
US8747854B2 (en) 2010-06-03 2014-06-10 Abbvie Biotechnology Ltd. Methods of treating moderate to severe hidradenitis suppurativa with anti-TNF-alpha antibodies
CA2803391C (en) 2010-06-22 2021-11-09 Neogenix Oncology, Inc. Npc1 antibodies that bind a muc5ac epitope
SI2593128T1 (en) 2010-07-15 2018-08-31 Adheron Therapeutics, Inc. Humanized antibodies targeting the EC1 Kaderina-11 domain and associated compositions and procedures
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
JP2013536175A (ja) 2010-07-16 2013-09-19 アブリンクス エン．ヴェー． 修飾された単一ドメイン抗原結合分子及びその使用
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
EP2420250A1 (de) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4-Antikörper
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
ME02678B (de) 2010-08-23 2017-06-20 Univ Texas Anti-ox40-antikörper und verfahren zu deren verwendung
MX350142B (es) 2010-08-23 2017-08-28 Wyeth Llc * Formulaciones estables de antigenos rlp2086 de neisseria meningitidis.
EP3549601B1 (de) 2010-09-10 2021-02-24 Wyeth LLC Non-lipidierten varianten von neisseria meningitidis orf2086 antigene
CA3182320A1 (en) 2010-09-23 2012-03-29 Precision Biologics, Inc. Colon and pancreas cancer peptidomimetics
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
AU2011319777B2 (en) 2010-10-27 2016-12-08 The Research Foundation For The State University Of New York Compositions targeting the soluble extracellular domain of E-cadherin and related methods for cancer therapy
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
WO2012068463A2 (en) 2010-11-18 2012-05-24 Beth Israel Deaconess Medicall Center, Inc. Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
MX361929B (es) 2010-11-19 2018-12-19 Eisai R&D Man Co Ltd Star Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
ES2847891T3 (es) 2010-11-23 2021-08-04 Vitaeris Inc Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral
KR101947356B1 (ko) 2010-11-23 2019-02-12 글락소 그룹 리미티드 온코스타틴 ｍ (ｏｓｍ)에 대한 항원 결합 단백질
CN103415615B (zh) 2010-11-24 2015-11-25 高红 扩增造血干细胞
KR20200023495A (ko) 2011-01-10 2020-03-04 더 리젠츠 오브 더 유니버시티 오브 미시간 줄기 세포 인자 억제제
ME02734B (de) 2011-01-14 2017-10-20 Ucb Biopharma Sprl Antikörpermodule zur bindung an il-17a und il-17f
AU2012209223B2 (en) 2011-01-24 2015-11-05 Abbvie Biotechnology Ltd Automatic injection devices having overmolded gripping surfaces
MY164530A (en) 2011-03-02 2017-12-29 Berg Llc Interrogatory cell-based assays and uses thereof
MX361242B (es) 2011-03-30 2018-11-30 Ablynx Nv Anticuerpos de dominio sencillo contra tnf-alfa y usos de los mismos.
US20120328567A1 (en) 2011-04-08 2012-12-27 Steven Bushnell Biomarkers predictive of therapeutic responsiveness to ifnb and uses thereof
CN103702682A (zh) 2011-04-21 2014-04-02 科罗拉多州立大学董事会法人团体 治疗视神经脊髓炎的组合物和方法
MX345747B (es) 2011-04-21 2017-02-14 Abbvie Inc Dispositivo de inyección automático portable.
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
KR102493433B1 (ko) 2011-05-02 2023-01-27 밀레니엄 파머슈티컬스 인코퍼레이티드 항-α4β7 항체에 대한 제형
US20140086827A1 (en) 2011-05-09 2014-03-27 The Cleveland Clinic Foundation Serum S100B And Uses Thereof
ES2704038T3 (es) 2011-05-24 2019-03-13 Zyngenia Inc Complejos multiespecíficos multivalentes y monovalentes y sus usos
JP6342325B2 (ja) 2011-05-25 2018-06-13 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 炎症性障害の治療のための抗ｋｉｒ抗体
LT3415531T (lt) 2011-05-27 2023-09-25 Glaxo Group Limited Bcma (cd269/tnfrsf17) – surišantys baltymai
EP2537933A1 (de) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Auf IL-15- und IL-15Ralpha-Sushi-Domäne basierende Immunozytokine
LT2726094T (lt) 2011-06-28 2017-02-10 Oxford Biotherapeutics Ltd Gydymo ir diagnozavimo objektas
AU2012275133B2 (en) 2011-06-30 2017-08-17 Genzyme Corporation Inhibitors of T-cell activation
EP3339325A1 (de) 2011-07-13 2018-06-27 UCB Biopharma SPRL Bakterienwirtsstamm zur expression von rekombinanter dsbc
EP2546267A1 (de) 2011-07-13 2013-01-16 UCB Pharma S.A. Bakterienwirtsstamm mit rekombinanter DsbC-Expression
US20150125533A1 (en) 2011-07-25 2015-05-07 American University In Cairo Single-domain antibodies and graphene coated magnetic metal nanoparticles conjugate and methods for using the same
WO2013028810A1 (en) 2011-08-22 2013-02-28 Cangene Corporation Clostridium difficile antibodies
EP3564261A1 (de) 2011-08-23 2019-11-06 Foundation Medicine, Inc. Kif5b-re-fusionsmoleküle und verwendungen davon
WO2013036596A2 (en) 2011-09-06 2013-03-14 Reed Guy L Serpinf2-binding molecules and methods of use
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US8969519B2 (en) 2011-09-13 2015-03-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using FNDC5
EP2771349B1 (de) 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatikverfahren zur bestimmung von peptidbindungen
WO2013038156A1 (en) 2011-09-16 2013-03-21 Ucb Pharma S.A. Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
AU2012311492A1 (en) 2011-09-23 2014-03-06 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5T4 and CD3
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
AU2012324495B2 (en) 2011-10-21 2016-04-21 Pfizer Inc. Addition of iron to improve cell culture
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
PL2780039T3 (pl) 2011-11-17 2018-03-30 Pfizer Inc. Cytotoksyczne peptydy i ich koniugaty przeciwciało lek
EP2599496A1 (de) 2011-11-30 2013-06-05 Kenta Biotech AG Neuartige Targets von Acinetobacter baumannii
US20150017157A1 (en) 2011-12-19 2015-01-15 Xoma (Us) Llc Methods for treating acne
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
EP2820047B1 (de) 2012-03-01 2018-04-25 Amgen Research (Munich) GmbH Langlebige polypeptidbindungsmoleküle
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX359256B (es) 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
US20140080180A1 (en) 2012-03-27 2014-03-20 Genentech, Inc. Harvest operations for recombinant proteins
WO2013150518A1 (en) 2012-04-01 2013-10-10 Rappaport Family Institute For Research In The Medical Sciences Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
KR20200105524A (ko) 2012-04-02 2020-09-07 버그 엘엘씨 조사적 세포 기반 분석 및 이의 사용
WO2013152011A1 (en) 2012-04-02 2013-10-10 Ab Biosciences, Inc. Novel human control antibodies and uses therefor
EP2834641A1 (de) 2012-04-02 2015-02-11 Gundersen Lutheran Health Systems, Inc. Reagenzien, verfahren und kits zur klassifizierung von krebs
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
AU2013262934B2 (en) 2012-05-14 2018-02-01 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
NZ724892A (en) 2012-05-15 2018-04-27 Seattle Genetics Inc Self-stabilizing linker conjugates
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
CN104619722B (zh) 2012-06-22 2022-10-04 达特茅斯大学理事会 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP3613765A1 (de) 2012-08-03 2020-02-26 Dana-Farber Cancer Institute, Inc. Antikörper gegen abstossungs führung molekül b (rgmb)
CA2882034C (en) 2012-08-16 2019-10-29 Ipierian, Inc. Methods of treating a tauopathy
WO2014029752A1 (en) 2012-08-22 2014-02-27 Glaxo Group Limited Anti lrp6 antibodies
EP2892558B1 (de) 2012-09-07 2019-04-10 The Trustees Of Dartmouth College Vista-modulatoren zur diagnose und behandlung von krebs
EP3677310A1 (de) 2012-10-08 2020-07-08 St. Jude Children's Research Hospital Therapien auf der basis der steuerung der stabilität und funktion regulatorischer t-zellen über eine neuropilin-1:semaphorin-achse
KR20210063443A (ko) 2012-10-09 2021-06-01 바이오젠 엠에이 인코포레이티드 탈수초성 질환의 치료를 위한 복합 요법 및 용도
CN110818798A (zh) 2012-10-25 2020-02-21 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
WO2014066733A2 (en) 2012-10-25 2014-05-01 Life Technologies Corporation Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins
AU2013337638B2 (en) 2012-11-02 2018-10-25 Bioverativ Usa Inc. Anti-complement C1s antibodies and uses thereof
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
AU2013340449B2 (en) 2012-11-05 2017-11-30 Pfizer Inc. Spliceostatin analogs
TWI589590B (zh) 2012-11-07 2017-07-01 輝瑞股份有限公司 抗切口３（ａｎｔｉ-ｎｏｔｃｈ３）抗體及抗體-藥物共軛體
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US10024844B2 (en) 2012-12-20 2018-07-17 Hospital For Special Surgery Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
US9938344B2 (en) 2012-12-28 2018-04-10 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
WO2014113729A2 (en) 2013-01-18 2014-07-24 Foundation Mecicine, Inc. Methods of treating cholangiocarcinoma
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
WO2014134179A1 (en) 2013-02-28 2014-09-04 The Board Of Regents Of The University Of Texas System Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
EP2964665B1 (de) 2013-03-08 2018-08-01 Pfizer Inc Immunogene fusionspolypeptide
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US9023353B2 (en) 2013-03-13 2015-05-05 The Board Of Trustees Of The University Of Arkansas Anti-(+)—methamphetamine monoclonal antibodies
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
AU2014236309A1 (en) 2013-03-14 2015-10-29 Ren Liu Cancer treatment using antibodies that bing cell surface GRP78
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
EP2970489A2 (de) 2013-03-15 2016-01-20 AbbVie Biotechnology Ltd Anti-cd25-antikörper und deren verwendungen
MX368665B (es) 2013-03-15 2019-10-10 Abbvie Biotherapeutics Inc Variantes de fc.
CN105358174B (zh) 2013-03-15 2019-03-15 酵活有限公司 具细胞毒性和抗有丝分裂的化合物以及其使用方法
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
AU2014233478A1 (en) 2013-03-15 2015-09-24 Abbvie Biotechnology Ltd. Anti-CD25 antibodies and their uses
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
HUE058364T2 (hu) 2013-04-19 2022-07-28 Cytune Pharma Citokinbõl származó kezelés redukált vaszkuláris permeabilitási szindrómával
US20160089434A1 (en) 2013-06-03 2016-03-31 Novartis Ag Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
EP3293275B1 (de) 2013-06-06 2021-08-04 Dana-Farber Cancer Institute, Inc. Zusammensetzung und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von krebs mit pd-l1-isoformen
CA2914768A1 (en) 2013-06-10 2014-12-18 Ipierian, Inc. Methods of treating a tauopathy
US9587032B2 (en) 2013-06-12 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University IgE antibodies for the inhibition of tumor metastasis
US9428748B2 (en) 2013-06-17 2016-08-30 Hong Gao Method of expanding hematopoietic stem cells
EP3011334A1 (de) 2013-06-20 2016-04-27 The Trustees Of The University Of Pennsylvania Verfahren zur diagnose von bauchspeicheldrüsenkrebs
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
AU2014296288B2 (en) 2013-07-31 2020-02-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using PTH-related and EGF-related molecules
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
AU2014326974B2 (en) 2013-09-24 2017-01-19 The Feinstein Institute For Medical Research Peptides inhibiting cold-inducible RNA binding protein activity
PT3049085T (pt) 2013-09-26 2021-10-01 Beth Israel Deaconess Medical Ct Inc Inibidores de sgk1 no tratamento da síndrome do qt longo
EP3757130A1 (de) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Verfahren zur behandlung von blutkrebs
NZ717668A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
KR102283408B1 (ko) 2013-11-15 2021-07-29 앵스티띠 파스퇴르 플라스모듐 팔시파룸 아르테미시닌 내성의 분자 마커
WO2015081085A2 (en) 2013-11-27 2015-06-04 Ipierian, Inc. Methods of treating a tauopathy
EP3080161B1 (de) 2013-12-09 2021-03-24 New York University Zusammensetzungen und verfahren zur phagozytenfreisetzung von antistaphylokokkenmittel
WO2015091653A2 (en) 2013-12-17 2015-06-25 Westfaelische Wilhelms-Universitaet Muenster Means and methods for treating a pruritus-like skin-disease
EP3082878B1 (de) 2013-12-19 2022-10-05 Seagen Inc. Methylencarbamat-linker zur verwendung mit gezielten wirkstoffkonjugaten
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
EP2960252A1 (de) 2014-06-26 2015-12-30 Institut Pasteur Phospholipase zur Behandlung von Immunosuppression
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
JP6590810B2 (ja) 2013-12-24 2019-10-16 ヤンセン ファーマシューティカ エヌブイ 抗ｖｉｓｔａ抗体および断片
PL3086815T3 (pl) 2013-12-27 2022-06-13 Zymeworks Inc. Układy łącznikowe dla koniugatów leków zawierające ugrupowanie sulfonamidowe
WO2015103026A2 (en) 2014-01-03 2015-07-09 The Regents Of The University Of Michigan Treatment of neurological disorders
JP6682438B2 (ja) 2014-01-09 2020-04-15 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッドＨａｄａｓｉｔ Ｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｓｅｒｖｉｃｅｓ ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｔｄ． 癌治療のための改善された細胞組成物および方法
EP3094736A4 (de) 2014-01-14 2017-10-25 Dana-Farber Cancer Institute, Inc. Zusammensetzungen und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von melanom mit pd-l1-isoformen
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
EP3099692B9 (de) 2014-01-27 2019-11-13 Pfizer Inc Bifunktionelle zytostatika
WO2015116753A1 (en) 2014-01-29 2015-08-06 Dana-Farber Cancer Institute, Inc. Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CA3212977A1 (en) 2014-02-11 2015-08-20 Visterra, Inc. Antibody molecules to dengue virus and uses thereof
SG11201605886RA (en) 2014-02-17 2016-09-29 Seattle Genetics Inc Hydrophilic antibody-drug conjugates
EP3145546B1 (de) 2014-02-19 2020-12-09 Emergent BioSolutions Canada Inc. Monoklonale marburg-antikörper
EP2915569A1 (de) 2014-03-03 2015-09-09 Cytune Pharma Reinigungsverfahren für Il-15/Il-15Ralpha-basierte Konjugate
AU2015229103C9 (en) 2014-03-14 2020-11-26 Immutep S.A.S Antibody molecules to LAG-3 and uses thereof
US10544395B2 (en) 2014-03-19 2020-01-28 Pfizer Inc. Method of cell culture
WO2015145449A2 (en) 2014-03-27 2015-10-01 Yeda Research And Development Co. Ltd. T-cell receptor cdr3 peptides and antibodies
SG11201607258SA (en) 2014-04-10 2016-10-28 Obi Pharma Inc Antibodies, pharmaceutical compositions and uses thereof
US11624093B2 (en) 2014-04-24 2023-04-11 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
WO2015164364A2 (en) 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
CR20160534A (es) 2014-04-27 2017-04-25 Ccam Biotherapeutics Ltd Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1)
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
IL248511B (en) 2014-05-13 2022-07-01 Bavarian Nordic As Combined therapy for the treatment of cancer with a focovirus expressing the antigen and a monoclonal antibody against tim-3
US10774387B2 (en) 2014-05-19 2020-09-15 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
MX2016016310A (es) 2014-06-11 2017-10-20 A Green Kathy Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
EP3808756A1 (de) 2014-07-17 2021-04-21 The Trustees of The University of Pennsylvania Verfahren zur verwendung von exosomen zur überwachung des zustands eines transplantierten organs
WO2016012623A1 (en) 2014-07-25 2016-01-28 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
MX2017001403A (es) 2014-07-31 2017-07-07 Amgen Res (Munich) Gmbh Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido.
TW201609812A (zh) 2014-07-31 2016-03-16 安美基研究（慕尼黑）公司 最佳化之跨物種特異性雙特異性單鏈抗體構築體
CN106794246B (zh) 2014-08-08 2021-10-15 OncoQuest制药有限公司 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
WO2016025202A1 (en) 2014-08-14 2016-02-18 The Regents Of The University Of Colorado Antibody-sirna conjugates and uses therefor
EP3186393A4 (de) 2014-08-25 2018-01-10 The Johns Hopkins University Verfahren und zusammensetzungen im zusammenhang mit prostatakrebstherapeutika
DK3189132T3 (da) 2014-09-04 2020-08-10 Stemcell Tech Inc Opløselige antistofkomplekser til T-celle- eller NK-celle-aktivering og -ekspansion
EP3925622A1 (de) 2014-09-13 2021-12-22 Novartis AG Kombinationstherapien
US10759860B2 (en) 2014-09-16 2020-09-01 Synermore Biologics Co., Ltd. Anti-EGFR antibody and uses of same
WO2016041082A1 (en) 2014-09-17 2016-03-24 CDRD Ventures, Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US20170209574A1 (en) 2014-10-03 2017-07-27 Novartis Ag Combination therapies
CA2963091A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
JP6574257B2 (ja) 2014-10-07 2019-09-11 アン アンド ロバート エイチ． ルーリー チルドレンズ ホスピタル オブ シカゴ 新規の抗Ｎｏｄａｌ抗体及びその使用方法
CA2963602A1 (en) 2014-10-09 2016-04-14 Dana-Farber Cancer Institute, Inc. Multiple-variable il-2 dose regimen for treating immune disorders
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
JP6951246B2 (ja) 2014-11-05 2021-10-20 アネクソン，インコーポレーテッド ヒト化抗補体因子Ｃ１ｑ抗体及びその使用
MX2017007136A (es) 2014-12-05 2017-12-04 Immunext Inc Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
WO2016094273A1 (en) 2014-12-08 2016-06-16 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
AU2016206682B2 (en) 2015-01-14 2021-11-11 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-LAP monoclonal antibodies
CN107405410B (zh) 2015-01-15 2021-08-10 OncoQuest制药有限公司 增加抗癌剂向靶递送的方法
DK3254110T3 (da) 2015-02-03 2020-05-18 Ventana Med Syst Inc Histokemisk test til vurdering af ekspression af programmeret død-ligand 1 (pd-l1)
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
CA2977499C (en) 2015-02-25 2023-10-03 Vanderbilt University Antibody-mediated neutralization of marburg virus
AU2016229238B2 (en) 2015-03-06 2022-06-02 Dana-Farber Cancer Institute, Inc. PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers
KR20170125941A (ko) 2015-03-06 2017-11-15 체에스엘 베링 리컴비넌트 퍼실리티 아게 개선된 반감기를 갖는 변형된 폰 빌레브란트 인자
JP6782250B2 (ja) 2015-03-20 2020-11-11 ファイザー・インク Ｃｔｉファーマコフォアを含有する二官能性細胞毒性剤
WO2016164358A1 (en) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
IL255076B2 (en) 2015-04-17 2023-10-01 Amgen Res Munich Gmbh CDH3 and CD3 bispecific antibody constructs
US10954515B2 (en) 2015-04-21 2021-03-23 Institut Gustave Roussy Therapeutic methods, products and compositions inhibiting ZNF555
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
EP3288584A2 (de) 2015-04-30 2018-03-07 President and Fellows of Harvard College Anti-ap2-antikörper und antigenbindemittel zur behandlung von stoffwechselerkrankungen
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
JP6851322B2 (ja) 2015-05-27 2021-03-31 ユーシービー バイオファルマ エスアールエル 神経疾患を治療する方法
CA2989963A1 (en) 2015-06-19 2016-12-22 Cytrx Corporation Delivery systems for controlled drug release
JP7026509B2 (ja) 2015-06-24 2022-02-28 ヤンセン ファーマシューティカ エヌブイ 抗ｖｉｓｔａ抗体およびフラグメント
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
KR20180025962A (ko) 2015-07-06 2018-03-09 유씨비 바이오파마 에스피알엘 타우 결합 항체
TN2017000543A1 (en) 2015-07-06 2019-04-12 Ucb Biopharma Sprl Tau-binding antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3316902A1 (de) 2015-07-29 2018-05-09 Novartis AG Kombinationstherapien mit antikörpermolekülen gegen tim-3
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EP3331536A4 (de) 2015-08-03 2019-03-27 The Regents of The University of California Zusammensetzungen und verfahren zur modulierung der abhd2-aktivität
EP3331918A1 (de) 2015-08-04 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Kombinationsbehandlungen und verwendungen und verfahren dafür
US20180222990A1 (en) 2015-08-04 2018-08-09 Glaxosmithkline Intellectual Property Development Limited Combination Treatments and Uses and Methods Thereof
WO2017021910A1 (en) 2015-08-04 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
BR112018002520A2 (pt) 2015-08-06 2018-09-18 Glaxosmithkline Ip Dev Ltd Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
TW201716084A (zh) 2015-08-06 2017-05-16 葛蘭素史克智慧財產發展有限公司 組合物及其用途與治療
WO2017021912A1 (en) 2015-08-06 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combined tlrs modulators with anti ox40 antibodies
WO2017031353A1 (en) 2015-08-19 2017-02-23 Rutgers, The State University Of New Jersey Novel methods of generating antibodies
KR20180042412A (ko) 2015-09-02 2018-04-25 이뮤텝 에스.에이.에스. 항-lag-3 항체
CN116063481A (zh) 2015-09-04 2023-05-05 普里玛托普医疗股份有限公司 人源化抗-cd40抗体及其用途
KR20230155021A (ko) 2015-09-15 2023-11-09 스칼러 락, 인크. 항-프로/잠재성-미오스타틴 항체 및 그의 용도
US10738334B2 (en) 2015-09-23 2020-08-11 Pfizer Inc. Cells having reduced BCAT1
CA3000531A1 (en) 2015-10-07 2017-04-13 Obi Pharma, Inc. Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
US11161912B2 (en) 2015-10-13 2021-11-02 Technion Research & Development Foundation Limited Heparanase-neutralizing monoclonal antibodies
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
WO2017072183A1 (en) 2015-10-27 2017-05-04 Ucb Biopharma Sprl Methods of treatment using anti-il-17a/f antibodies
WO2017075329A2 (en) 2015-10-29 2017-05-04 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
BR112018008799A2 (pt) 2015-10-30 2019-01-15 Glaxosmithkline Ip Dev Ltd método de prognóstico
CN107043406B (zh) 2015-11-03 2021-08-17 财团法人工业技术研究院 化合物、连接子-药物、及配体-药物耦合体
US20180320136A1 (en) 2015-11-03 2018-11-08 GlycoMimitics, Inc. Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
CA3004438A1 (en) 2015-11-09 2017-05-18 The Children's Hospital Of Philadelphia Glypican 2 as a cancer marker and therapeutic target
KR20180101341A (ko) 2015-11-10 2018-09-12 비스테라, 인크. 리포폴리사카라이드에 특이적으로 결합하는 항체 분자-약물 접합체 및 그의 용도
SI3380522T1 (sl) 2015-11-25 2024-02-29 Visterra, Inc. Molekule protitelesa proti APRIL in uporabe le-teh
WO2017093942A1 (en) 2015-12-01 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
WO2017096311A1 (en) 2015-12-04 2017-06-08 Seattle Genetics, Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US20180371093A1 (en) 2015-12-17 2018-12-27 Novartis Ag Antibody molecules to pd-1 and uses thereof
RU2018125603A (ru) 2015-12-17 2020-01-21 Новартис Аг Комбинация ингибитора с-мет с молекулой антитела к pd-1 и ее применения
WO2017106806A1 (en) 2015-12-18 2017-06-22 Federica Cavallo COMPOSITIONS AND METHODS RELATED TO xCT PEPTIDES
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP3184544A1 (de) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein-v-inhibitoren zur verwendung als koagulansien
WO2017120523A2 (en) 2016-01-08 2017-07-13 Scholar Rock, Inc. Anti-pro/latent myostatin antibodies and methods of use thereof
WO2017134547A1 (en) 2016-02-01 2017-08-10 Pfizer Inc. Tubulysin analogs and methods for their preparation
MD3411402T2 (ro) 2016-02-03 2022-05-31 Amgen Res Munich Gmbh Constructe de anticorpi bispecifici BCMA și CD3 de angajare a celulei T
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TN2018000266A1 (en) 2016-02-03 2020-01-16 Amgen Res Munich Gmbh Psma and cd3 bispecific t cell engaging antibody constructs.
EP3410849B1 (de) 2016-02-05 2023-07-05 Institut Pasteur Verwendung von inhibitoren von adam12 als adjuvanzien in tumortherapien
TW202216201A (zh) 2016-02-12 2022-05-01 比利時商楊森製藥公司 抗vista抗體及片段、其用途及鑑定其之方法
EP3207937A1 (de) 2016-02-17 2017-08-23 Royal College of Surgeons in Ireland Verfahren zur behandlung oder prävention von sepsis
JP2019509282A (ja) 2016-02-29 2019-04-04 ファウンデーション・メディシン・インコーポレイテッド 癌の治療方法
EP4043492A1 (de) 2016-03-01 2022-08-17 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Gegen humanen poliovirus-rezeptor (pvr) spezifische antikörper
WO2017156263A1 (en) 2016-03-09 2017-09-14 Memorial Sloan-Kettering Cancer Center Enigma and cdh18 as companion diagnostics for cdk4 inhibitors
AU2017229991A1 (en) 2016-03-10 2018-10-04 Aperisys, Inc. Antigen-binding fusion proteins with modified HSP70 domains
JP2019509737A (ja) 2016-03-11 2019-04-11 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． ＴＧＦβ１結合性免疫グロブリンおよびその使用
TN2018000301A1 (en) 2016-03-14 2020-01-16 Univ Oslo Engineered immunoglobulins with altered fcrn binding
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
JP7049311B2 (ja) 2016-03-17 2022-04-06 ヌマブ イノヴェイション アーゲー 抗ＴＮＦα抗体およびそれらの機能的断片
EP3430042B1 (de) 2016-03-17 2023-05-24 Numab Innovation AG Anti-tnf-alpha-antikörper und funktionale fragmente davon
WO2017158436A1 (en) 2016-03-17 2017-09-21 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
WO2017158101A1 (en) 2016-03-17 2017-09-21 Numab Innovation Ag ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
PT3219727T (pt) 2016-03-17 2021-01-21 Tillotts Pharma Ag Anticorpos anti-tnf alfa e fragmentos funcionais dos mesmos
DK3219726T3 (da) 2016-03-17 2020-12-07 Tillotts Pharma Ag Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf
CN109153728A (zh) 2016-03-21 2019-01-04 埃尔斯塔治疗公司 多特异性和多功能分子及其用途
JP7073266B2 (ja) 2016-03-25 2022-05-23 シージェン インコーポレイテッド Ｐｅｇ化薬物リンカー及びその中間体を調製するためのプロセス
TW202302144A (zh) 2016-03-25 2023-01-16 美商威特拉公司 登革病毒的抗體分子之配方設計
IL311675A (en) 2016-04-04 2024-05-01 Bioverativ Usa Inc Anti-complement factor BB antibodies and their uses
SG11201808356UA (en) 2016-04-05 2018-10-30 Pfizer Cell culture process
EP3439692A4 (de) 2016-04-08 2020-01-22 ITI Health, Inc. Plectin-1-antikörper und verwendungen davon
WO2017181098A2 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
RU2021111187A (ru) 2016-04-15 2021-04-29 Янссен Фармасьютикалз, Инк. Антитела против человеческого vista и их применение
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
CA3024027A1 (en) 2016-05-11 2017-11-16 Amgen Inc. Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
WO2017203051A1 (en) 2016-05-26 2017-11-30 University College Cork - National University Of Ireland, Cork An engineered gram positive bacterium
US11534496B2 (en) 2016-06-07 2022-12-27 The Brigham And Women's Hospital, Inc. Compositions and methods relating to T peripheral helper cells in autoantibody-associated conditions
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
EP3472210A1 (de) 2016-06-17 2019-04-24 Life Technologies Corporation Stellenspezifische vernetzung von antikörpern
WO2017221072A2 (en) 2016-06-21 2017-12-28 University Of Oslo Hla binding vaccine moieties and uses thereof
MA45668A (fr) 2016-07-13 2019-05-22 Biogen Ma Inc Schémas posologiques d'antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation
CN109641947B (zh) 2016-07-20 2023-04-14 犹他大学研究基金会 Cd229 car t细胞及其使用方法
EP3494134A1 (de) 2016-08-02 2019-06-12 Visterra, Inc. Manipulierte polypeptide und verwendungen davon
JP2018058822A (ja) 2016-08-03 2018-04-12 ファイザー・インク ヘテロアリールスルホンをベースとするコンジュゲーションハンドル、これらの調製のための方法、および抗体薬物コンジュゲートの合成におけるこれらの使用
MA45945A (fr) 2016-08-09 2019-06-19 Seattle Genetics Inc Conjugués de médicaments avec des lieurs auto-stabilisants, aux propriétés physiochimiques améliorées
MA45934A (fr) 2016-08-10 2019-06-19 Centre Nat Rech Scient Procédés et réactifs utilisés pour la détection du paludisme à plasmodium falciparum résistant à la pipéraquine
PL3497132T3 (pl) 2016-08-15 2020-11-30 Novartis Ag Schematy i sposoby leczenia stwardnienia rozsianego z zastosowaniem ofatumumabu
WO2018038684A1 (en) 2016-08-26 2018-03-01 Agency For Science, Technology And Research Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
EP3293271A1 (de) 2016-09-12 2018-03-14 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Marker und target als eine diagnosevariable und target zur therapie von metastatischem krebs
WO2018057618A1 (en) 2016-09-20 2018-03-29 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
CN118005799A (zh) 2016-09-23 2024-05-10 马伦戈治疗公司 包含λ轻链和κ轻链的多特异性抗体分子
MA46359A (fr) 2016-09-29 2019-08-07 Amgen Inc Protéines de liaison à l'antigène à viscosité faible et leurs procédés de préparation
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
IL265957B2 (en) 2016-10-12 2024-04-01 Bioverativ Usa Inc Anti-C1S antibodies and methods of using them
MA46660A (fr) 2016-10-18 2019-08-28 Seattle Genetics Inc Administration ciblée d'inhibiteurs de la voie de récupération de nicotinamide adénine dinucléotide
JP2020500878A (ja) 2016-12-01 2020-01-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 併用療法
EP3548068A1 (de) 2016-12-01 2019-10-09 GlaxoSmithKline Intellectual Property Development Limited Kombinationstherapie
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
CN110300761B (zh) 2016-12-15 2023-05-09 国家生物技术研究所公司 抗pcna单克隆抗体及其用途
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
CN118047864A (zh) 2016-12-23 2024-05-17 百时美施贵宝公司 用于改进生物分析和生物加工特性的治疗性免疫球蛋白g4的设计
US11820979B2 (en) 2016-12-23 2023-11-21 Visterra, Inc. Binding polypeptides and methods of making the same
KR102616666B1 (ko) 2016-12-23 2023-12-27 노파르티스 아게 인자 xi 항체 및 사용 방법
SI3565592T1 (sl) 2017-01-06 2023-05-31 Scholar Rock, Inc. Zdravljenje presnovnih bolezni z zaviranjem aktivacije miostatina
PT3565592T (pt) 2017-01-06 2023-05-31 Scholar Rock Inc Tratamento de doenças metabólicas através da inibição da ativação da miostatina
CN117398457A (zh) 2017-01-06 2024-01-16 供石公司 亚型特异性、背景许可性TGFβ1抑制剂及其用途
EP3568411B1 (de) 2017-01-13 2024-03-06 Pietro P. Sanna Verfahren und zusammensetzungen zur behandlung von hpa-hyperaktivität
AU2018209940A1 (en) 2017-01-18 2019-07-11 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
CN110461860A (zh) 2017-01-24 2019-11-15 辉瑞公司 卡奇霉素衍生物及其抗体药物缀合物
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
US20180221476A1 (en) 2017-02-06 2018-08-09 Oncoquest Nc. Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
US20190375847A1 (en) 2017-02-15 2019-12-12 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
JP7116736B2 (ja) 2017-03-02 2022-08-10 ノバルティス アーゲー 操作されたヘテロ二量体タンパク質
WO2018165649A1 (en) 2017-03-10 2018-09-13 Embera Neurotherapeutics, Inc. Pharmaceutical compositions and uses thereof
JP7293122B2 (ja) 2017-03-14 2023-06-19 バイオベラティブ・ユーエスエイ・インコーポレイテッド 補体が媒介する疾患および障害を処置するための方法
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
CA3056182A1 (en) 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
IL269398B2 (en) 2017-03-24 2024-05-01 Seagen Inc A process for the preparation of glucuronide-drug binders and their intermediates
EP3599843A4 (de) 2017-03-24 2021-01-13 The Regents of the University of California Proteoglycan-irregularitäten in abnormalen fibroblasten und darauf basierende therapien
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
KR20200020662A (ko) 2017-04-03 2020-02-26 온콜로지, 인크. 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
US20200071417A1 (en) 2017-04-19 2020-03-05 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
CN110799529A (zh) 2017-04-22 2020-02-14 免疫治疗有限公司 改良lamp构建物
MA51189A (fr) 2017-04-27 2020-03-04 Seattle Genetics Inc Conjugués d'inhibiteur de la voie de récupération du nicotinamide adénine dinucléotide quaternarisé
EP3615065A1 (de) 2017-04-28 2020-03-04 Amgen Inc. Hilfsstoffe zur verringerung der viskosität von antikörperformulierungen und formulierungszusammensetzungen
AU2018260545B2 (en) 2017-04-28 2023-11-23 Marengo Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
IL297073B2 (en) 2017-05-02 2023-12-01 Immunomic Therapeutics Inc LAMP constructs containing cancer antigens
BR112019022751A2 (pt) 2017-05-05 2020-05-19 Amgen Inc composição farmacêutica compreendendo construtos de anticorpos biespecíficos para armazenamento e administração melhorados
EP3624848A1 (de) 2017-05-19 2020-03-25 Syndax Pharmaceuticals, Inc. Kombinationstherapien
CN110753703B (zh) 2017-05-23 2024-04-09 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） 新的cd73抗体、其制备和用途
KR102344616B1 (ko) 2017-05-30 2021-12-31 더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마 항-더블코르틴-유사 키나제 1 항체 및 사용 방법
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
EP3634496A4 (de) 2017-06-06 2021-09-08 Dana-Farber Cancer Institute, Inc. Verfahren zur sensibilisierung von krebszellen gegen t-zell-vermittelte abtötung mittels modulierung von molekularen signalwegen
US11325957B2 (en) 2017-06-19 2022-05-10 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors
CN110785187B (zh) 2017-06-22 2024-04-05 诺华股份有限公司 针对cd73的抗体分子及其用途
EP3642240A1 (de) 2017-06-22 2020-04-29 Novartis AG Antikörpermoleküle gegen cd73 und verwendungen davon
US20200223924A1 (en) 2017-06-27 2020-07-16 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
WO2019005503A1 (en) 2017-06-29 2019-01-03 Rutgers, The State University Of New Jersey COMPOSITIONS AND METHODS TARGETING G12 SIGNALING FOR BRONCHODILATORY THERAPY
EP3431496A1 (de) 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-isoasp7-amyloid-beta-antikörper und verwendungen davon
KR20200031659A (ko) 2017-07-20 2020-03-24 노파르티스 아게 항-lag-3 항체의 투여 요법 및 그의 용도
WO2019023661A1 (en) 2017-07-28 2019-01-31 Scholar Rock, Inc. SPECIFIC INHIBITORS OF TGF-BETA 1 LTBP COMPLEX AND USES THEREOF
JP6889328B2 (ja) 2017-07-31 2021-06-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 三次元構造に基づくヒト化方法
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
CA3075717A1 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
JP2020533382A (ja) 2017-09-14 2020-11-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌の組合せ治療
CN111107874A (zh) 2017-09-14 2020-05-05 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
JP2020533983A (ja) 2017-09-15 2020-11-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 目的のポリペプチドのラージスケールの製造間のオンラインバイオマス静電容量モニタリング
LT3681483T (lt) 2017-09-15 2022-09-12 Amgen Inc. Terapinio baltymo farmacinės formos liofilizavimo būdas
EP3461841B1 (de) 2017-10-02 2019-09-11 Certest Biotec, S.L. Antikörper gegen dps und testvorrichtungen zum nachweis von bakterien der gattung campylobacter
SG11202002248TA (en) 2017-10-02 2020-04-29 Visterra Inc Antibody molecules to cd138 and uses thereof
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
BR112020007046A2 (pt) 2017-10-19 2020-11-17 Debiopharm International S.A. produto de combinação para o tratamento do câncer
WO2019077165A1 (en) 2017-10-20 2019-04-25 Institut Curie DAP10 / 12-BASED CHIMERIC ANTIGENIC RECEPTORS (CAR) ADAPTED FOR RUSH
EP3697811A1 (de) 2017-10-20 2020-08-26 Institut Curie Hakenfusionsprotein zur regulierung der zellulären transportsteuerung eines zielproteins
EP3706795A4 (de) 2017-11-09 2021-10-13 Pinteon Therapeutics Inc. Verfahren und zusammensetzungen zur erzeugung und verwendung von humanisierten konformationsspezifischen phosphorylierten tau-antikörpern
KR20200089286A (ko) 2017-11-16 2020-07-24 노파르티스 아게 조합 요법
MX2020005658A (es) 2017-11-30 2020-11-11 Centurion Biopharma Corp Profarmacos de union a albumina de derivados de auristatina e.
US11572373B2 (en) 2017-11-30 2023-02-07 Ladrx Corporation Maytansinoid-based drug delivery systems
WO2019106605A1 (en) 2017-12-01 2019-06-06 Board Of Regents, The University Of Texas System Combination treatment for cancer
WO2019113464A1 (en) 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
EA202091422A1 (ru) 2017-12-11 2020-08-28 Эмджен Инк. Способ непрерывного производства продуктов на основе биспецифических антител
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
US20210251899A1 (en) 2018-01-25 2021-08-19 Acm Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
US11834487B2 (en) 2018-02-12 2023-12-05 Hadasit Medical Research Services & Development Ltd. Modulation of SLAMF6 splice variants for cancer therapy
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
CN111989339A (zh) 2018-02-20 2020-11-24 西雅图基因公司 疏水性奥瑞他汀f化合物及其缀合物
CA3092037A1 (en) 2018-02-21 2019-08-29 Celgene Corporation Bcma-binding antibodies and uses thereof
EP3755712A1 (de) 2018-02-21 2020-12-30 Cell Design Labs, Inc. Chimäre transmembranrezeptoren und verwendungen davon
EP3530282A1 (de) 2018-02-27 2019-08-28 Diaccurate Therapeutische verfahren
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20210009711A1 (en) 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
EP3765076A1 (de) 2018-03-16 2021-01-20 Bristol-Myers Squibb Company Reduktion der metabolischen enzymaktivität und der disulfidbindung während der proteinherstellung
JP2021519443A (ja) 2018-03-26 2021-08-10 グリカノスティックス エス・アール・オーＧｌｙｃａｎｏｓｔｉｃｓ Ｓ．Ｒ．Ｏ． タンパク質糖鎖プロファイリングの手段及び方法
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
EP3785732A4 (de) 2018-04-24 2022-02-23 Ampsource Biopharma Shanghai Inc. Antikörper gegen tim-3 und anwendung davon
AU2019264965A1 (en) 2018-05-09 2020-11-19 Nectin Therapeutics Ltd. Antibodies specific to human Nectin4
JP2021523185A (ja) 2018-05-15 2021-09-02 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アレルゲンを含む改善されたｌａｍｐ構築物
CA3101553A1 (en) 2018-05-31 2019-12-05 Glaxosmithkline Intellectual Property Development Limited Combination of a type ii protein arginine methyltransferase inhibitor and an icos binding protein to treat cancer
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
JP2021525271A (ja) 2018-05-31 2021-09-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｉｃｏｓ結合タンパク質及びアルギニンメチルトランスフェラーゼ阻害剤を用いた複合療法
WO2019236417A1 (en) 2018-06-04 2019-12-12 Biogen Ma Inc. Anti-vla-4 antibodies having reduced effector function
JP2021526014A (ja) 2018-06-05 2021-09-30 アムジエン・インコーポレーテツド 抗体依存性細胞貪食の調節
TW202015740A (zh) 2018-06-07 2020-05-01 美商西雅圖遺傳學公司 喜樹鹼結合物
CA3104295A1 (en) 2018-06-19 2019-12-26 Atarga, Llc Antibody molecules to complement component 5 and uses thereof
WO2019244107A1 (en) 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
WO2020008083A1 (es) 2018-07-05 2020-01-09 Consejo Superior De Investigaciones Científicas Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
EP3820896A1 (de) 2018-07-11 2021-05-19 Scholar Rock, Inc. Tgfbeta1-inhibitoren und verwendung davon
RS62914B1 (sr) 2018-07-11 2022-03-31 Scholar Rock Inc Izoform selektivni inhibitori tgfbeta1 i njihova upotreba
CA3105988A1 (en) 2018-07-11 2020-01-16 Abhishek Datta High-affinity, isoform-selective tgf.beta.1 inhibitors and use thereof
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
JP2021532140A (ja) 2018-07-30 2021-11-25 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３３及びｃｄ３に結合する二重特異性抗体コンストラクトの長期投与
AU2019314999A1 (en) 2018-08-03 2021-02-11 Amgen Inc. Antibody constructs for CLDN18.2 and CD3
WO2020030571A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
WO2020031087A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
WO2020030570A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
MX2021002332A (es) 2018-08-27 2021-08-11 Affimed Gmbh Células nk crioreservadas precargadas con una construcción de anticuerpo.
US20220033511A1 (en) 2018-09-11 2022-02-03 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
WO2020053325A1 (en) 2018-09-12 2020-03-19 Acm Biolabs Pte Ltd Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
WO2020053808A1 (en) 2018-09-12 2020-03-19 Georg Dewald Method of diagnosing vasoregulatory disorders
JP7465272B2 (ja) 2018-09-27 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体
AR116548A1 (es) 2018-09-28 2021-05-19 Amgen Inc Anticuerpos contra bcma soluble
AU2019354101A1 (en) 2018-10-05 2021-04-15 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
AU2019356564A1 (en) 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
US20220144941A1 (en) 2018-10-16 2022-05-12 UCB Biopharma SRL Method for the treatment of myasthenia gravis
JP2022513374A (ja) 2018-10-22 2022-02-07 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 投薬
SG11202104010PA (en) 2018-10-23 2021-05-28 Scholar Rock Inc Rgmc-selective inhibitors and use thereof
WO2020089794A1 (en) 2018-10-31 2020-05-07 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
JP2022507744A (ja) 2018-11-20 2022-01-18 バヴァリアン・ノルディック・アクティーゼルスカブ ４－１ｂｂｌ（ｃｄ１３７ｌ）及び／またはｃｄ４０ｌをコードする組み換えｍｖａの腫瘍内及び／または静脈内投与によって、がんを治療する療法
WO2020115655A1 (en) 2018-12-06 2020-06-11 Pfizer Inc. Cells with reduced inhibitor production and methods of use thereof
WO2020128898A1 (en) 2018-12-20 2020-06-25 Novartis Ag Pharmaceutical combinations
CN113301954A (zh) 2019-01-13 2021-08-24 耶路撒冷希伯来大学伊森姆研究发展有限公司 特异性针对人类连接蛋白-2的抗体
EP3689905A3 (de) 2019-01-30 2021-02-24 Scholar Rock, Inc. Ltbp-komplex-spezifische inhibitoren von tgf-beta und verwendungen davon
AU2020214412A1 (en) 2019-02-01 2021-08-12 Glaxosmithkline Intellectual Property Development Limited Belantamab mafodotin in combination with pembrolizumab for treating cancer
EP3693063A1 (de) 2019-02-06 2020-08-12 Diaccurate Verfahren und zusammensetzungen zur behandlung von krebs
EP3924739A1 (de) 2019-02-12 2021-12-22 Biogen MA Inc. Biomarker von progressiver multifokaler leukoenzephalopathie
WO2020168059A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Claudin 6 antibodies and uses thereof
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
US11254736B2 (en) 2019-02-15 2022-02-22 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
TWI756633B (zh) 2019-02-15 2022-03-01 大陸商上海藥明生物技術有限公司 具有改善的同質性的抗體－藥物綴合物、其藥物組合物、用途和製備方法
AU2020226904A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
JP2022522662A (ja) 2019-02-21 2022-04-20 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
JP2022521750A (ja) 2019-02-21 2022-04-12 マレンゴ・セラピューティクス，インコーポレーテッド カルレティキュリンに結合する多機能性分子およびその使用
JP2022521937A (ja) 2019-02-21 2022-04-13 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN113677708A (zh) 2019-03-26 2021-11-19 亚狮康私人有限公司 采用抗il13r抗体或其结合片段的治疗
AU2020253833A1 (en) 2019-03-29 2021-10-28 Atarga, Llc Anti FGF23 antibody
MA55529A (fr) 2019-04-03 2022-02-09 Genzyme Corp Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
WO2020208572A1 (en) 2019-04-10 2020-10-15 Glaxosmithkline Intellectual Property Development Limited Combination therapy with an anti bcma antibody and a gamma secretase inhibitor
CN114007642A (zh) 2019-04-30 2022-02-01 森迪生物科学公司 嵌合受体及其使用方法
US20220289854A1 (en) 2019-04-30 2022-09-15 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
CA3139809A1 (en) 2019-05-10 2020-11-19 Takeda Pharmaceutical Company Limited Antibody drug conjugates
TW202045711A (zh) 2019-06-13 2020-12-16 美商安進公司 生物製品製造中基於生物量之自動灌注控制
JP2022537289A (ja) 2019-06-17 2022-08-25 ビステラ， インコーポレイテッド Ｃｄ１３８に対するヒト化抗体分子およびその使用
AU2020317009A1 (en) 2019-07-19 2022-02-03 The Board Of Trustees Of The Leland Stanford Junior University Chimeric antigen receptors containing Glypican 2 binding domains
TW202118774A (zh) 2019-07-26 2021-05-16 美商威特拉公司 介白素-2藥劑及其用途
WO2021018941A1 (en) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
KR20220041915A (ko) 2019-08-06 2022-04-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 바이오제약 조성물 및 관련 방법
EP4031658A1 (de) 2019-08-07 2022-07-27 DB Biotech, AS Verbesserte meerrettichperoxidase-polypeptide
CN114555637A (zh) 2019-08-12 2022-05-27 比昂生物制剂公司 针对ilt2的抗体及其用途
EP4025303A1 (de) 2019-09-04 2022-07-13 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Herv-inhibitoren zur verwendung bei der behandlung von tauopathien
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
WO2021046293A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab
CA3152946A1 (en) 2019-09-10 2021-03-18 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
EP3792632A1 (de) 2019-09-16 2021-03-17 Vito NV Immuntherapiemarker
AR120079A1 (es) 2019-09-19 2022-02-02 Seattle Genetics Inc Liberación selectiva de fármacos de conjugados internalizados de compuestos biológicamente activos
WO2021058711A2 (en) 2019-09-27 2021-04-01 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
CN114746119A (zh) 2019-09-27 2022-07-12 詹森生物科技公司 抗-ceacam抗体及其用途
JP2022550851A (ja) 2019-10-04 2022-12-05 シージェン インコーポレイテッド カンプトテシンペプチドコンジュゲート
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
WO2021077051A1 (en) 2019-10-18 2021-04-22 Immunomic Therapeutics, Inc Improved lamp constructs comprising cancer antigens
BR112022007179A2 (pt) 2019-10-21 2022-08-23 Novartis Ag Inibidores de tim-3 e usos dos mesmos
AU2020370086A1 (en) 2019-10-21 2022-05-19 Novartis Ag Combination therapies with venetoclax and TIM-3 inhibitors
CA3156683A1 (en) 2019-11-13 2021-05-20 Amgen Inc. METHOD FOR REDUCING AGGREGATE FORMATION IN DOWNSTREAM PROCESSING OF BI-SPECIFIC ANTIGEN-BINDING MOLECULES
US20230190922A1 (en) 2019-11-20 2023-06-22 Bavarian Nordic A/S Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
IL293640A (en) 2019-12-20 2022-08-01 Amgen Inc CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
EP4076660A1 (de) 2019-12-20 2022-10-26 Novartis AG Verwendung von anti-tgf-beta-antikörpern und checkpoint-inhibitoren zur behandlung von proliferativen erkrankungen
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
EP4081554A1 (de) 2019-12-27 2022-11-02 Affimed GmbH Verfahren zur herstellung eines bispezifischen fcyriii-x-cd30-antikörper-konstrukts
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
US20230090552A1 (en) 2020-01-08 2023-03-23 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
CA3167427A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgfb inhibitors and use thereof
US20230050148A1 (en) 2020-01-11 2023-02-16 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
TW202140553A (zh) 2020-01-13 2021-11-01 美商威特拉公司 C5ar1抗體分子及其用途
US20230058489A1 (en) 2020-01-17 2023-02-23 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
US20230093169A1 (en) 2020-01-22 2023-03-23 Amgen Research (Munch) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
JP2023512023A (ja) 2020-01-28 2023-03-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 併用療法及びその使用及び方法
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
KR20230004453A (ko) 2020-02-25 2023-01-06 메디보스턴 리미티드 캄프토테신 유도체 및 이의 접합체
WO2021183861A1 (en) 2020-03-12 2021-09-16 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
CA3175275A1 (en) 2020-03-19 2021-09-23 Amgen Inc. Antibodies against mucin 17 and uses thereof
US11815513B2 (en) 2020-04-01 2023-11-14 Institut Pasteur Severe acute respiratory syndrome (SARS)-associated coronavirus diagnostics
US20210311054A1 (en) 2020-04-01 2021-10-07 Institut Pasteur Severe acute respiratory syndrome (sars) - associated coronavirus diagnostics
CN116710146A (zh) 2020-04-03 2023-09-05 威特拉公司 抗体分子-药物偶联物及其用途
KR20220164787A (ko) 2020-04-06 2022-12-13 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 암 및 감염의 치료를 위한 NKp46에 대한 항체 및 이의 작제물
BR112022020332A2 (pt) 2020-04-10 2022-12-13 Seagen Inc Composto conjugado anticorpo-droga, composição, método de tratamento de câncer e de um distúrbio autoimune
WO2021209358A1 (en) 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein
WO2021209357A1 (en) 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
JP2023521227A (ja) 2020-04-14 2023-05-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 癌の併用療法
CN115667300A (zh) 2020-04-17 2023-01-31 硕腾服务有限责任公司 猫抗体变异体
EP4136106A1 (de) 2020-04-17 2023-02-22 Zoetis Services LLC Hundeantikörpervarianten
WO2021209824A1 (en) 2020-04-17 2021-10-21 Institut Pasteur Methods and products for serological analysis of sars-cov-2 infection
WO2021217085A1 (en) 2020-04-24 2021-10-28 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
WO2021220215A1 (en) 2020-05-01 2021-11-04 Novartis Ag Engineered immunoglobulins
US20230167193A1 (en) 2020-05-01 2023-06-01 Novartis Ag Immunoglobulin variants
AU2021275049A1 (en) 2020-05-19 2022-12-22 Amgen Inc. MAGEB2 binding constructs
WO2021239666A1 (en) 2020-05-26 2021-12-02 Diaccurate Therapeutic methods
US20240209085A1 (en) 2020-05-29 2024-06-27 Amgen Inc. Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
EP4161653A1 (de) 2020-06-03 2023-04-12 Bionecure Therapeutics, Inc. Trophoblastzelloberflächenantigen-2 (trop-2)-antikörper
BR112022026639A2 (pt) 2020-06-24 2023-05-09 Visterra Inc Moléculas de anticorpos para april e seus usos
WO2022005883A1 (en) 2020-06-29 2022-01-06 Zoetis Services Llc Feline antibody variants for improving stability
US20230256114A1 (en) 2020-07-07 2023-08-17 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
WO2022008976A1 (en) 2020-07-10 2022-01-13 Institut Pasteur Use of gdf11 to diagnose and treat anxiety and depression
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
EP4193153A1 (de) 2020-08-06 2023-06-14 Bioverativ USA Inc. Entzündungszytokine und ermüdung bei patienten mit komplementvermittelter erkrankung
CA3190634A1 (en) 2020-08-12 2022-02-17 Biond Biologics Ltd. Antibodies against ilt2 and use thereof
WO2022046922A2 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
JP2023540248A (ja) 2020-08-26 2023-09-22 マレンゴ・セラピューティクス，インコーポレーテッド Ｔｒｂｃ１またはｔｒｂｃ２を検出する方法
CA3190755A1 (en) 2020-08-26 2022-03-03 Andreas Loew Multifunctional molecules that bind to calreticulin and uses thereof
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4204021A1 (de) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Verfahren zur behandlung von psma-exprimierenden krebsarten
CA3192526A1 (en) 2020-09-04 2022-03-10 Rutgers, The State University Of New Jersey Sars-cov-2 vaccines and antibodies
WO2022058621A1 (en) 2020-09-21 2022-03-24 Theravectys High throughput methods and products for sars-cov-2 sero-neutralization assay
CA3194936A1 (en) 2020-09-28 2022-03-31 Zoetis Services Llc Canine antibody variants
TW202413413A (zh) 2020-09-29 2024-04-01 美商碩騰服務公司 貓抗體變異體
DE102020125465A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202229312A (zh) 2020-09-29 2022-08-01 德商英麥提克生物技術股份有限公司 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
MX2023004436A (es) 2020-10-15 2023-05-08 UCB Biopharma SRL Moleculas de union que multimerizan cd45.
WO2022081436A1 (en) 2020-10-15 2022-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
EP4237081A1 (de) 2020-11-02 2023-09-06 UCB Biopharma SRL Verwendung von anti-trem1-neutralisierenden antikörpern zur behandlung neurodegenerativer erkrankungen von motoneuronen
EP4240407A1 (de) 2020-11-06 2023-09-13 Amgen Inc. Antigenbindende domäne mit reduzierter clipping-rate
JP2023547661A (ja) 2020-11-06 2023-11-13 アムジエン・インコーポレーテツド Ｃｄ３に結合するポリペプチド構築物
WO2022096716A2 (en) 2020-11-06 2022-05-12 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
WO2022096700A1 (en) 2020-11-06 2022-05-12 Amgen Research (Munich) Gmbh Polypeptide constructs selectively binding to cldn6 and cd3
WO2022097117A1 (en) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Ltd. Antibody drug conjugates
KR20230110297A (ko) 2020-11-20 2023-07-21 조에티스 서비시즈 엘엘씨 소 항체 변이체
AU2021391924A1 (en) 2020-12-04 2023-06-22 The General Hospital Corporation Methods of using interleukin-2 agents
JP2023551983A (ja) 2020-12-07 2023-12-13 ユーシービー バイオファルマ エスアールエル インターロイキン－２２に対する抗体
MX2023006650A (es) 2020-12-07 2023-06-21 UCB Biopharma SRL Anticuerpos multiespecificos y combinaciones de anticuerpos.
AU2021400322A1 (en) 2020-12-18 2023-06-22 Zoetis Services Llc Mutations in feline antibody constant regions
EP4277665A1 (de) 2021-01-13 2023-11-22 Memorial Sloan Kettering Cancer Center Anti-dll3-antikörper-wirkstoff-konjugat
AU2022207708A1 (en) 2021-01-13 2023-07-27 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
EP4277904A1 (de) 2021-01-15 2023-11-22 Seagen Inc. Immunmodulatorische antikörper-wirkstoff-konjugate
KR20230147072A (ko) 2021-01-20 2023-10-20 비스테라, 인크. 인터류킨-2 돌연변이체 및 이의 용도
JP2024504696A (ja) 2021-01-20 2024-02-01 バイオアントレ エルエルシー Ｃｔｌａ４結合性タンパク質およびがんを処置する方法
CA3208998A1 (en) 2021-01-22 2022-07-28 Steven Kerrigan Treatment of coronavirus
EP4284825A2 (de) 2021-01-28 2023-12-06 Zoetis Services LLC Mutationen in konstanten regionen von hundeantikörpern
WO2022162569A1 (en) 2021-01-29 2022-08-04 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
WO2022170002A1 (en) 2021-02-03 2022-08-11 Seagen Inc. Immunostimulatory compounds and conjugates
JP2024507124A (ja) 2021-02-11 2024-02-16 ネクチン セラピューティクス リミテッド Ｃｄ１１２ｒに対する抗体およびその使用
WO2022182872A2 (en) 2021-02-24 2022-09-01 Alladapt Immunotherapeutics, Inc. Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
WO2022186773A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
WO2022186772A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
EP4301777A1 (de) 2021-03-02 2024-01-10 Dana-Farber Cancer Institute, Inc. Verfahren zur behandlung von erythrozytenerkrankungen
EP4308171A1 (de) 2021-03-18 2024-01-24 Seagen Inc. Selektive wirkstofffreisetzung aus internalisierten konjugaten biologisch aktiver verbindungen
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
US20240166747A1 (en) 2021-03-31 2024-05-23 Glazosmithkline Intellectual Property Development Limited Antigen binding proteins and combinations thereof
CN117241828A (zh) 2021-03-31 2023-12-15 美国比奥维拉迪维股份有限公司 减少冷凝集素病患者的手术相关溶血
EP4067381A1 (de) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Neue tnfr2-bindende moleküle
CA3215594A1 (en) 2021-04-02 2022-10-06 Agnieszka KIELCZEWSKA Mageb2 binding constructs
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
JP2024515591A (ja) 2021-04-08 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｔｃｒに結合する多機能性分子およびその使用
CA3214934A1 (en) 2021-04-12 2022-10-20 Madhavan Nallani Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
EP4334355A1 (de) 2021-05-03 2024-03-13 UCB Biopharma SRL Antikörper
CA3217180A1 (en) 2021-05-06 2022-11-10 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
WO2022251850A1 (en) 2021-05-28 2022-12-01 Seagen Inc. Anthracycline antibody conjugates
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
JP2024524159A (ja) 2021-06-23 2024-07-05 スカラー ロック インコーポレイテッド 代謝障害の治療における使用のためのｇｌｐ－１経路活性化剤と組み合わせたミオスタチン経路阻害剤
WO2023278377A1 (en) 2021-06-29 2023-01-05 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
KR20240034234A (ko) 2021-07-14 2024-03-13 2세븐티 바이오, 인코포레이티드 항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체
WO2023007023A1 (en) 2021-07-30 2023-02-02 Affimed Gmbh Duplexbodies
CN117794954A (zh) 2021-08-03 2024-03-29 葛兰素史密斯克莱知识产权发展有限公司 生物药物组合物和稳定同位素标记肽图谱方法
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
WO2023025927A1 (en) 2021-08-26 2023-03-02 Glycanostics S.R.O Glycoprotein biomarkers for diagnosing cancer
CA3231890A1 (en) 2021-09-14 2023-03-23 Jan Tkac Use of lectins to determine mammaglobin-a glycoforms in breast cancer
EP4405396A2 (de) 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von her2-positivem krebs
WO2023048651A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd Method for treatment of moderate to severe atoptic dematitis
WO2023048650A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
GB202115122D0 (en) 2021-10-21 2021-12-08 Dualyx Nv Binding molecules targeting IL-2 receptor
TW202333784A (zh) 2021-10-29 2023-09-01 新加坡商亞獅康私人有限公司 抗ｉｌ１３ｒ抗體調配物
IL312060A (en) 2021-11-03 2024-06-01 Affimed Gmbh Bispecific CD16A binders
KR20240099407A (ko) 2021-11-03 2024-06-28 아피메트 게엠베하 이중특이적 cd16a 결합제
WO2023079058A1 (en) 2021-11-05 2023-05-11 Yokogawa Insilico Biotechnology Gmbh Cell culture with reduced production of lactate
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
US20230348614A1 (en) 2021-11-24 2023-11-02 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
CA3238574A1 (en) 2021-12-01 2023-06-08 Gregory Babcock Methods of using interleukin-2 agents
WO2023105528A1 (en) 2021-12-12 2023-06-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to ceacam1
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2023140780A1 (en) 2022-01-24 2023-07-27 Aslan Pharmaceuticals Pte Ltd. Method of treating inflammatory disease
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
US20230383010A1 (en) 2022-02-07 2023-11-30 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
WO2023163659A1 (en) 2022-02-23 2023-08-31 Aslan Pharmaceuticals Pte Ltd Glycosylated form of anti-il13r antibody
WO2023175614A1 (en) 2022-03-15 2023-09-21 Yeda Research And Development Co. Ltd. Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
TW202400137A (zh) 2022-03-17 2024-01-01 美商思進公司 喜樹鹼偶聯物
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
WO2023212518A1 (en) 2022-04-25 2023-11-02 Visterra, Inc. Antibody molecules to april and uses thereof
WO2023215740A1 (en) 2022-05-06 2023-11-09 Seagen Inc. Immunomodulatory antibody-drug conjugates
WO2023218027A1 (en) 2022-05-12 2023-11-16 Amgen Research (Munich) Gmbh Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023223092A1 (en) 2022-05-18 2023-11-23 Institut Pasteur Identification of a human circovirus
WO2023240287A1 (en) 2022-06-10 2023-12-14 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
WO2023245048A1 (en) 2022-06-15 2023-12-21 Bioverativ Usa Inc. Anti-complement c1s antibody formulation
EP4296279A1 (de) 2022-06-23 2023-12-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-transthyretin(ttr)-bindende proteine und ihre verwendungen
US20240025978A1 (en) 2022-06-24 2024-01-25 Bioverativ Usa Inc. Methods for treating complement-mediated diseases
GB202210679D0 (en) 2022-07-21 2022-09-07 Dualyx Nv Binding molecules targeting il-12rb2
US20240108744A1 (en) 2022-07-27 2024-04-04 Mediboston Limited Auristatin derivatives and conjugates thereof
WO2024030577A1 (en) 2022-08-03 2024-02-08 Seagen Inc. Immunostimulatory anti-pd-l1-drug conjugates
WO2024030976A2 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier
EP4321522A1 (de) 2022-08-12 2024-02-14 Seagen Inc. Zytotoxische verbindungen und konjugate davon
WO2024043837A1 (en) 2022-08-26 2024-02-29 Aslan Pharmaceuticals Pte Ltd High concentration anti-il13r antibody formulation
WO2024054157A1 (en) 2022-09-06 2024-03-14 Aslan Pharmaceuticals Pte Ltd Treatment for sleep loss or sleep disturbance in patients with dermatitis
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition
WO2024062074A1 (en) 2022-09-21 2024-03-28 Sanofi Biotechnology Humanized anti-il-1r3 antibody and methods of use
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
WO2024138076A1 (en) 2022-12-22 2024-06-27 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation
WO2024133858A1 (en) 2022-12-22 2024-06-27 Julius-Maximilians-Universität-Würzburg Antibodies for use as coagulants

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54145289A (en) * 1977-11-08 1979-11-13 Genentech Inc Improving method of microbiological polypeptide displaying method and means
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4464465A (en) * 1982-04-05 1984-08-07 Genetic Systems Corporation Cell-driven viral transfer in eukaryotes
DE3369466D1 (en) * 1982-05-12 1987-03-05 Harvard College Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof
US4520226A (en) * 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
JPS5965099A (ja) * 1982-10-05 1984-04-13 Takeda Chem Ind Ltd 発現用プロモ−タ−およびその用途
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4703004A (en) * 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法

Also Published As

Publication number Publication date
DE3587524T3 (de) 2002-06-20
JP2714786B2 (ja) 1998-02-16
JPS62500352A (ja) 1987-02-19
JP2865645B2 (ja) 1999-03-08
DE3587524D1 (de) 1993-09-16
GB8608827D0 (en) 1986-05-14
EP0194276A1 (de) 1986-09-17
EP0194276B1 (de) 1993-08-11
DE3587524T2 (de) 1994-01-20
GB2177096B (en) 1989-05-17
GB2177096A (en) 1987-01-14
JPH10155482A (ja) 1998-06-16
GB8422238D0 (en) 1984-10-10
EP0194276B2 (de) 2002-01-16
WO1986001533A1 (en) 1986-03-13

Similar Documents

Publication Publication Date Title
ATE92959T1 (de) Herstellung von chimaeren antikoerpern.
Schubert Immunoglobulin biosynthesis: IV. Carbohydrate attachment to immunoglobulin subunits
AU3066489A (en) Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
FR14C0070I1 (fr) Procede de la production des anticorps humanises
KR920000789A (ko) 면역글로불린 부분을 갖는 융합 단백질, 이의 제조방법 및 용도
KR880006357A (ko) 인터류킨-i에 대한 항체
GB2137631B (en) Multichain polypeptides and processes for their production
DE60039596D1 (de) Verfahren zur herstellung von monoklonalen antikörpern
DE3580654D1 (de) Menschlicher hybridomfusionspartner zur herstellung menschlicher monoklonaler antikoerper.
IL93118A0 (en) Expression vectors,cells transformed thereby and their use in the production of chimeric monoclonal antibodies
ATE196162T1 (de) Toxoplasma gondii-antigene, ihre herstellung und ihre verwendung
MX26714A (es) Procedimiento para la preparacion de albumina de SUERO HUMANO VECTOR Y PLASMIDO USADOS ASI COMO LEVADURA METILOTROFICA TRANSFORMADA OBTENIDA
EP0494702A3 (en) Production of factor xiiia by gene technology
PT733643E (pt) Polipeptido proteico membranar possuindo funcao de suporte do crescimento de pre-celulas b e gene para este
ES2075068T3 (es) Procedimiento de preparacion de una proteina mediante levaduras que utiliza un sistema inducible, vectores y cepas transformadas correspondientes.
DK189987A (da) Fremgangsmaade til fremstilling af peptider
DE3685145D1 (de) Monoklonale antikoerper gegen atriale, natriurethische peptide.
DE69332321D1 (de) Prostaglandin-E-Rezeptoren, deren DNA und Herstellung
ATE131494T1 (de) Herstellung von fusionsproteinen oder - polypeptiden
Pénit et al. Purification and properties of chick terminal deoxynucleotidyl transferase (TdT)
EP0287012A3 (de) Monoklonaler Anti-R-Binder-Antikörper, Verfahren zu seiner Herstellung und seine Verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification

Ref document number: 0194276

Country of ref document: EP

EELA Cancelled due to lapse of time